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Down syndrome (DS) is caused by three copies of human chromosome 21 (Hsa21) and 
results in phenotypes including intellectual disability. Ts65Dn mice, the most extensively studied 
DS model, have three copies of ~50% of the genes on Hsa21 and display many phenotypes 
associated with DS, including cognitive deficits.  DYRK1A is a dosage-sensitive gene found in 
three copies in humans with Trisomy 21 and in Ts65Dn mice and is involved in CNS 
development.  Overexpression of DYRK1A is hypothesized to cause many of the cognitive and 
developmental deficits observed in DS and has been touted as a target for drug development in 
DS.  Definitive evidence that excessive expression/activity of Dyrk1a directly contributes to 
specific phenotypes in DS mouse models is limited, and there is no direct evidence that verified 
pharmacological inhibition of Dyrk1a in vivo causes enduring improvement in DS cognitive 
phenotypes. In part, this reflects the remarkably limited knowledge of the temporal regulation of 
Dyrk1a expression and activity in different brain regions across development in DS mouse models. 
To establish the therapeutic potential of Dyrk1a inhibitors, the first aim of this study was to 
determine when and in what brain regions excessive Dyrk1a is evident and to identify 
developmental periods when elevated expression of Dyrk1a may be contributing to enduring 
aberrant functional development. This aim provided systematic quantification of Dyrk1a protein 
level at key postnatal (P) ages (P12, P15, P18, P24 P30, P42) in Ts65Dn mice, at ages of 
translational relevance to clinical applications in humans (birth, early adolescence, late 
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adolescence, young adult).  Western blot analysis showed that significant elevation of Dyrk1a with 
the largest effect sizes occurred in trisomic mice on P15.  The second aim of this study was to test 
whether treating Ts65Dn with a novel Dyrk1a inhibitor (CX-4945) during the time of Dyrk1a 
elevation would rescue the behavioral and structural abnormalities observed.  From P14-P18, 
Ts65Dn and euploid mice were treated with 75mg/kg CX-4945 or DMSO (vehicle) and tested on 
a homing task and locomotor activity in a novel arena on P17-P18, counterbalanced for order.  At 
the cessation of treatment, hippocampal cell proliferation was assessed.  While there was a lack of 
statistically significant improvements with CX-4945 treatment, there were modest effect sizes.  In 
addition, several of the behavioral studies were significantly underpowered, making it difficult to 
conclusively ascertain the efficacy of CX-4945 on specific phenotypes.  Nevertheless, this study 
demonstrates that Dyrk1a is dynamically expressed across development in mice, and suggests that 
consideration of the spatial and temporal expression of Dyrk1a may well be critical in the 
development of therapeutics for DS.   
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CHAPTER 1. INTRODUCTION  
1.1 Down syndrome 
Down syndrome (DS) occurs in approximately 1 in every 700 live births and results from 
the triplication of Hsa21 (Parker et al., 2010).  The genetic basis of DS was discovered in 1958 by 
Jerome Lejeune who observed an extra copy of Hsa21 in human tissue samples (Lejeune et al., 
1959).  The most common cause of DS is a maternal non-disjunction of Hsa21 during meiosis, 
where Hsa21 does not separate (three copies of long arm Hsa21) (Epstein, 2001).  Hsa21 was one 
of the first chromosomes to be sequenced and contains 218 protein coding and 280 non-protein 
coding genes (Hattori et al., 2000; Gupta et al., 2016).  Currently, the only known risk factor of 
DS is advanced maternal age (Yoon et al., 1996; Allen et al., 2009).  
DS results in an array of phenotypes that affect the cardiovascular, skeletal and central 
nervous systems.  Heart defects affect 40-50% of children with DS (Freeman et al., 2008; Freeman 
et al., 1998; Tubman et al., 1991).  Bone deficits, including a reduction in bone mineral density, 
an increased incidence of osteoporosis, and altered craniofacial development are also observed 
(Guijarro et al., 2008; Center et al., 1998; Richtsmeier et al., 2000).  Individuals with DS have 
significantly higher body mass index (BMI) levels and an increased predisposition to obesity than 
the general population (Artioli et al., 2017).  Other phenotypes such as hearing loss (75%), 
obstructive sleep apnea (50%-80%) and eye disease (60%) (Bull, 2011; Källén et al., 1996; Marcus 
et al., 1991; Netzer et al., 2010; Shott et al., 2001; Zigman et al., 2007; Leverenz et al., 1998) are 
also observed in individuals with DS.  Adults with DS are at a high risk of developing Alzheimer-
disease (AD) pathology, including accumulation of amyloid-β (Aβ) plaques in the brain and the 
presence of neurofibrillary tangles (Hartley et al., 2015; Zigman, 2013; Zigman et al., 2007).  A 
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significantly lower intelligence quotient (IQ) is present in nearly all individuals with DS, although 
there is a range of IQs reported (Carr et al., 2018; Silverman, 2007).  These phenotypes are 
common among individuals with DS but there is variability in the incidence and severity of the 
various phenotypes (Roubertoux et al., 2006). 
1.2 Structural and histological phenotypes observed in DS 
The intellectual disability phenotype observed in nearly all individuals with DS is 
hypothesized to be caused by developmental deficits in brain structures such as the hippocampus, 
cerebral cortex and cerebellum.  Deficits in these brain structures are observed in fetuses with DS 
beginning at ~17-21 weeks gestation, with a reduction in brain size and the volume and number of 
proliferating cells in the hippocampus, dentate gyrus (DG) and parahippocampal gyrus, as well as 
a smaller population of neuronal cells versus controls (Guidi et al., 2008; Contestabile et al., 2007; 
Larsen et al., 2008; Sylvester, 1983).  Delays in myelin formation, decreased density of myelinated 
axons in the hilus of the DG, decreased neuronal and synaptic density, and synaptic length in the 
DG have been observed at ~20 weeks (Ábrahám et al., 2012).   
These histological deficits extend into postnatal development, as 3-5 months old infants 
with DS display a smaller brain stem and cerebellum, as well as a lower brain weight.  These 
infants also display deficits in myelination within the brain stem, cerebellum, spinal cord and 
posterior horn (Wisniewski, 1989).  Post mortem analysis of fetuses at birth through childhood 
show fewer neurons, lower neuronal density, decreased synaptic density and synaptic length 
(Schmidt-Sidor et al., 1990).   Children and young adults with DS exhibit reductions in 
hippocampal, cerebellar and cerebral volume, as well as increases in subcortical gray matter 
volumes versus controls (Jernigan et al., 1993; Pinter et al., 2001; Pinter et al., 2001).     
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Adults with DS exhibit a lower brain weight, as well as deficits in hippocampal, cerebellar, 
cerebral cortex, corpus callosum, and white matter volumes versus age matched controls (Teipel 
et al., 2003).  Individuals with DS have been shown to develop Alzheimer-like pathology, 
including plaques and neurofibrillary tangles before the age of 40.  These phenotypes occur in 
multiple areas of the brain, including the cerebral cortex and the DG of the hippocampal formation 
(Motte et al., 1989; Hof et al., 1995). 
1.3 Cognitive and behavioral phenotypes in individuals with DS 
Accompanying the reduced IQ, individuals with DS display deficits on a range of cognitive 
function [for extensive review see (Godfrey et al., 2018)].  Infants with DS display developmental 
learning delays in tasks such as the object-concept task and recognition memory tasks (Miranda et 
al., 1974; Nygaard et al., 2001; Milojevich et al., 2016), although these deficits may be dependent 
on the memory retention interval (Roberts et al., 2015). Visuospatial memory may be preserved in 
children with DS, as there were no reported deficits on a computer version of the Corsi block-
tapping task versus controls (Jarrold et al., 1997; Vicari et al., 1995; Numminen et al., 2001; Laws, 
2002).  However, deficits are apparent when these tasks are utilized in a “real-world” space, 
requiring the integration of environmental cues to learn the task (Mangan, 1992).  Young adults 
with DS display impairments on verbal working memory, verbal and non-verbal long-term 
memory tasks, as well as associative memory and spatial long-term memory tasks (Carlesimo et 
al., 1997; Pennington et al., 2003; Munir et al., 2000).  These deficits are observed in adults with 
DS with impairments on both explicit and implicit verbal, non-verbal and working memory tasks 
(Jarrold et al., 2002; Lavenex et al., 2015; Jarrold et al., 2002; Vicari et al., 2005).  Individuals 
with DS also display performance deficits on tasks such as the virtual Morris water maze (MWM), 
CANTAB Pattern Recognition Memory Test, and the NEPSY List-Learning Test (Carlesimo et 
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al., 1997; Pennington et al., 2003).  These laboratory tasks are commonly used to assess several 
facets of memory function (recognition and declarative memory) because individuals with 
hippocampal damage show impairments on these tasks (Koehler et al., 1998; Goodrich‐Hunsaker 
et al., 2010; Broadbent et al., 2004).  Thus, the poorer performance on these tasks by individuals 
with DS may be due to hippocampal dysfunction. 
Linking these memory deficits to a specific anatomical deficit has yielded mixed results.  
A negative correlation between parahippocampal gyrus size (measured via MRI) and cognitive 
ability has been suggested, as well as a positive correlation between corpus callosum size and 
cognitive ability (Teipel et al., 2003).   However, the same study reported no correlations between 
cerebral size, cerebellar hemisphere size, or hippocampal size and cognitive ability (Teipel et al., 
2003).  While individuals with DS display brain-region specific abnormalities across development, 
future studies should aim to link structural and function impairments in specific neural circuits to 
specific memory or cognitive phenotypes.   
There are limitations in studies assessing neurocognition in individuals with DS, including 
a lack of longitudinal studies, the inclusion of appropriate age-matched (chronological and/or 
mental) controls, and the utilization of neurocognitive assessments that can engage and challenge 
an individual with DS and an age-matched control in the same study (Godfrey and Lee, 2018).  To 
address this problem, the Arizona Cognitive Test Battery (ACTB) was developed to specifically 
assess neurocognition in individuals with DS (Edgin et al., 2010).  The ACTB has demonstrated 
strong test-retest reliability, was designed to be applicable to a wide range of ages and skills, and 
have specific correlates to brain regions that are likely to be targeted with therapeutics (Edgin et 
al., 2010; Edgin et al., 2017).  Parallel to the development of the ACTB, the National Institutes of 
Health (NIH) formed a group that included DS researchers and pharmaceutical companies to create 
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a standard set of outcome measures for clinical trials in DS (Esbensen et al., 2017).  The ACTB 
has also been adapted to characterize neurobehavioral deficits in the Ts65Dn mouse model of DS 
in order to mimic phenotypes that are observed in the clinical setting (Hunsaker et al., 2016).  The 
development and utilization of these standard assessments will allow pre-clinical and clinical DS 
researchers to strengthen the evaluation and interpretation of new therapeutics for DS. 
1.4 The Ts65Dn mouse model of DS 
The development of DS mouse models has been instrumental for correlating the direct 
effects of trisomic gene expression on development and function.  These models are based on the 
orthologous genes between Hsa21 and mouse chromosomes 16 (Mmu16), Mmu17 and Mmu10 
(Pletcher et al., 2001).  Early development of these models largely focused on Mmu16, as this 
chromosome carries the majority of the homologs found on Hsa21 (Antonarakis et al., 2004).  
However, mice with a full triplication of Mmu16 do not survive postnatally, and carried three 
copies of hundreds of genes not homologous to Hsa21. Thus, a better model would be a mouse 
with segmental trisomy for just the distal region of Mmu16 that is homologous to Hsa21 (Epstein 
et al., 1985).  In order to produce offspring that contained a translocated chromosome containing 
the distal end of Mmu16, the testes of DBA/2J (D2) mice were irradiated and crossed with 
C57BL/6J (B6) females.  While several translocations were identified, T65 offspring contained a 
translocation that resulted in an extra chromosome that contained genes from the distal end of 
Mmu16 attached to the centromeric end of Mmu17 (Davisson et al., 1990).  These offspring were 
later renamed Ts (1716) 65Dn and were maintained by crossing to C57BL/6J x B6C3HF1 hybrid 
mice (Davisson et al., 1993; Davisson et al., 1990).  This model carries an extra segment of 
Mmu16, containing ~90 protein-coding Hsa21 gene homologs (Gupta et al., 2016).  This model 
also carries an extra centromeric region of Mmu17, resulting in three copies of non-DS related 
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genes including ~35 protein-coding genes, 15 non-protein-coding genes and 10 pseudogenes 
(Duchon et al., 2011). 
In addition to the Ts65Dn model, over 30 different mouse models of DS have been 
developed containing specific genetic segments of Mmu16, Mmu17 or Mmu10 including the 
Ts1Cje, Dp1Yey, Ts1Rhr, Ts1Yah [extensively reviewed in (Herault et al., 2017; Gardiner et al., 
2010)].  Recent advances in engineering DS mouse models also include the generation of the 
Tc(Hsa21)1TybEmcf, or Tc1 mouse model.  The Tc1 mouse was the first transchromosomic 
mouse line, and this model contained a freely segregating copy of Hsa21 (O'Doherty et al., 2005).  
However, there were several unexpected duplications and deletions observed, and these mice lose 
a copy of Hsa21 in certain cells, resulting in mosaicism (Gribble et al., 2013; O'Doherty et al., 
2005).  A triple trisomic mouse has also been created, providing a model that is trisomic for the 
Mmu10, Mmu16 and Mmu17 chromosome regions that contain Hsa21 homologs (Yu et al., 2010).  
However, the generation of these models is difficult and can be extremely time consuming to 
produce  (Chen et al., 2013).  While these and other mouse models are valuable in comparative 
research on genotype-phenotype correlations observed in DS, the Ts65Dn mouse model is the most 
extensively studied and widely used animal model of DS because it recapitulates most of the DS 
phenotypes, including craniofacial and skeletal abnormalities, developmental delays, low body 
weight, cognitive and behavioral impairments, and brain abnormalities (Baxter et al., 2000; 
Belichenko et al., 2004; Cooper et al., 2001; Reeves et al., 1995).  The developmental, behavioral 
and histological deficits exhibited by Ts65Dn mice have been extensively reviewed elsewhere 
(Gupta et al., 2016; Rueda et al., 2012).  Importantly, the Ts65Dn mouse is the model most often 
used to test treatments to improve the various deficits observed in DS (Gardiner, 2015).   
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1.5 Treatments for DS 
To date, there have been over 30 different therapeutics administered to mouse models of 
DS, with a handful administered to individuals with DS in a clinical setting.  The majority of these 
therapeutics focus on targeting specific neurotransmitter systems or aberrant neural pathways such 
as antagonists of GABAA, or NMDA receptors (memantine), serotonin reuptake inhibitors 
(fluoxetine), anti-inflammatories (minocycline), and free radical scavengers (melatonin) 
(Extensively reviewed by (Gardiner, 2015; Stagni et al., 2015; Costa et al., 2013).  Despite 
individuals with DS and Ts65Dn mice displaying neurodevelopmental deficits at fetal and neonatal 
stages, there is a significant imbalance in the number of studies administering treatments during 
these critical developmental ages.  A recent review evaluated 55 studies that administered a 
therapeutic to Ts65Dn mice and found that almost 70% of these studies were conducted in adult 
mice.  Therapeutics administered to adult Ts65Dn mice may modulate existing brain circuitry and 
rescue cognitive and behavioral deficits (Stagni et al., 2015).  Developing therapeutics for adult 
Ts65Dn mice is critical, considering the high co-morbidity of DS and AD (Choong et al., 2015).  
However, interventions during key periods of Ts65Dn brain development during prenatal or 
neonatal ages are likely to have long-lasting impact on developmental trajectories and subsequent 
phenotypes, and provide an alternative means for intervening in the aberrant brain development 
associated with the Ts65Dn phenotype.  For example, a single treatment injection with the Sonic 
hedgehog pathway activator SAG at birth significantly rescued granule cell precursor populations 
in the cerebellum at P6 and normalized cerebellar morphology when mice were aged to 4 months 
(Roper et al., 2006; Das et al., 2013; Gutierrez-Castellanos et al., 2013).  Two separate studies 
examined the effects of a daily (P3-P15) fluoxetine or epigallocatechin-3-gallate (EGCG) injection 
in Ts65Dn mice.  Both fluoxetine and EGCG rescued deficits in hippocampal neurogenesis in P15 
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Ts65Dn mice (Bianchi et al., 2010; Stagni et al., 2016).  In both studies, a separate group of mice 
were aged to ~P45 after the cessation of treatment at P15 in order to determine any long-term 
effects on behavior.  However, only fluoxetine restored hippocampal neurogenesis and 
hippocampal-dependent task deficits in adult (~P45) Ts65Dn mice (Bianchi et al., 2010; Guidi et 
al., 2013; Stagni et al., 2016).  The success of these studies during neonatal or perinatal ages 
highlight the existence of potentially critical time points for therapeutic intervention in DS and 
offer new opportunities for investigators.  
The majority of therapeutics to date administered to Ts65Dn mice across ages have targeted 
specific neurotransmitter systems or aberrant neural pathways, based on their contribution to 
cognitive and behavioral phenotypes.  An alternate treatment approach would be to target a gene 
or set of genes hypothesized to have a major influence on a phenotype due to its developmental 
overexpression in DS (Korbel et al., 2009; Lyle et al., 2009).  The goal of this approach is to target 
trisomic DS genes by identifying contributions of that gene’s overexpression to the emergence of 
primary phenotypes and correcting these phenotypes, rather than secondary phenotypes that can 
be caused downstream of an elevated gene (Roper et al., 2006).  However, the presence of a 
triplicated gene does not mean that it will alter development and function in every cell across 
development.  Thus, it is critical to identify the spatial and temporal expression of a trisomic gene 
in conjunction with specific phenotypes, in order to understand when the trisomic gene(s) cause(s) 
divergence from normal patterns of development (Roper and Reeves, 2006).   
1.6 What is DYRK1A? 
Dual-specificity tyrosine phosphorylation-regulated kinases (DYRKs) are a family of 
protein kinases that phosphorylate serine and threonine residues in a number of substrates (Becker 
et al., 2011).  Dual specificity tyrosine kinase 1A (DYRK1A) is the only DYRK located on Hsa21, 
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and is found in three copies in individuals with DS (Becker et al., 1999).  DYRK1A is a protein 
kinase that contains a catalytic kinase domain, two nuclear localization signals, a PEST motif 
containing amino acids (proline, glutamate, serine and threonine), histidine repeats, and serine and 
threonine residues (Alvarez et al., 2003).  DYRK1A is defined as a dual-specificity kinase because 
of its ability to phosphorylate on both serine/threonine residues, and it undergoes 
autophosphorylation on tyrosine residues in its activation loop (Alvarez et al., 2007).  DYRK1A 
autophosphorylates independently of upstream regulators, and this autophosphorylation is crucial 
for DYRK1A to switch from active to inactive states (Himpel et al., 2001; Becker et al., 1998; 
Becker et al., 2011). DYRK1A phosphorylates a multitude of substrates such as splicing proteins, 
transcription factors, and cell cycle proteins (for extensive review see (Park et al., 2009; Wiseman 
et al., 2009; Tejedor et al., 2011; Becker et al., 2014).   
The interest in DYRK1A started in Drosophila research when it was observed that flies 
with a mutant Minibrain (mnb) gene developed an abnormal spacing of neuroblasts within the 
brain and produced fewer neurons than controls (Tejedor et al., 1995).   It was hypothesized that 
the altered expression or activity of this mnb gene played a crucial role in normal Drosophila brain 
development.  Homologous genes to Mnb, renamed DYRK1A, were identified with very high 
degrees of conservation across species (mice, rat and human DYRK1A), allowing subsequent 
studies to determine the role of DYRK1A during neurodevelopment (Kentrup et al., 1996; 
Guimerâ et al., 1996; Shindoh et al., 1996).  Alternative splicing of Dyrk1a results in five known 
isoforms (OMIM: 60085). 
The causative role of DYRK1A overexpression in DS phenotypes originated from early 
genotype-phenotype mapping studies in individuals with segmental trisomy of Hsa21.  People with 
segmental trisomies containing DYRK1A exhibited developmental and cognitive phenotypes like 
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individuals with DS who carried a full triplication of Hsa21 gene (Korbel et al., 2009; Lyle et al., 
2009).  This genotype-phenotype correlation is supported by the high levels of expression of 
Dyrk1a in the CNS during development and the deleterious phenotypes that occur when DYRK1A 
levels are either elevated or decreased in mouse models (for review see (Stringer et al., 2017)).  
This dosage sensitivity is also observed in humans with a deletion of DYRK1A, who exhibit 
microcephaly, intellectual disability and epilepsy (Bon et al., 2011; Courcet et al., 2012; Møller et 
al., 2008).  The mechanism by which DYRK1A causes or influences these deleterious phenotypes 
is not well known.  However, its wide range of cellular substrates, combined with the presence of 
DYRK1A in three copies in individuals with DS and mouse models of DS has fueled the publication 
of over 68 studies on Dyrk1a and its involvement in DS-related processes and phenotypes (search 
was conducted in PubMed on 4-19-18 using terms: [title] Down syndrome AND Dyrk1a).  In 
parallel, there has been a steady production of Dyrk1a kinase inhibitors within the past 5 years 
(Becker et al., 2014; Smith et al., 2012; Nguyen et al., 2017).  However, there is growing evidence 
that triplicated genes in DS and Ts65Dn mouse models like DYRK1A, are not always significantly 
elevated versus controls (Cheon et al., 2003; Ahmed et al., 2015; Stringer et al., 2017).  Despite 
evidence that Dyrk1a is not significantly elevated in all tissues at all times, Dyrk1a inhibitors 
continue to be tested in mouse models of DS without regard for the tissue-specific temporal or 
spatial expression profile of Dyrk1a.  This approach makes it difficult to ascertain the link between 
pharmacological actions and any phenotypic therapeutic effects mediated effects on Dyrk1a 
expression/activity.  
11 
 
A recent review published by Stringer et al (2017) discusses the current implications of 
Dyrk1a overexpression in DS-related phenotypes, and highlights the large gap in knowledge about 
the spatial and temporal patterns of expression and tissue-specific levels of Dyrk1a protein over 
development in various mouse models of DS.  This review constructively addresses these gaps by 
detailing a framework for future studies assessing the effectiveness of a Dyrk1a inhibitor to target 
Dyrk1a activity in a mouse model of DS.  The framework articulated in that review helps advance 
our knowledge and development of targeted therapeutics with the hopes of improving the lives of 
individuals with DS. 
1.7 Targeting trisomic treatments: optimizing Dyrk1a inhibition to improve Down 
syndrome deficits 
 
 
This chapter includes the publication [Targeting trisomic treatments: optimizing Dyrk1a inhibition 
to improve Down syndrome deficits/Stringer, Megan, Charles R. Goodlett, Randall J. 
Roper/Molecular Genetics & Genomic Medicine/ Sep; 5(5):451-465. Copyright © [2017] [Randall 
J. Roper] 
Link: http://onlinelibrary.wiley.com/doi/10.1002/mgg3.334/full 
1.8 Current status of Dyrk1a inhibitors 
Several small molecule inhibitors have been developed to inhibit Dyrk1a activity.  One of 
the most selective Dyrk1a inhibitors available is the plant alkaloid harmine; however, it also is a 
potent inhibitor of monoamine oxidase A (MAO-A), which greatly limits its in vivo application 
(Kim et al., 1997; Adayev et al., 2011).  There has been a significant emphasis on developing other 
inhibitors as effective as harmine that lack inhibition of MAO-A.  The molecule (1Z)-1-(3-ethyl-
5-hydroxy-2(3H)-benzothiazoylidene)-2-propanone (INDY), inhibits Dyrk1a activity in vitro at 
similar concentrations as harmine and does not have inhibitory effects on MAO-A (Ogawa et al., 
2010).  When an additional acetyl group was added to INDY to increase its cell membrane 
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permeability (proINDY), this molecule was able to normalize developmental deformities in 
Xenopus laevis embryos that overexpressed Dyrk1a (Ogawa et al., 2010).  Another potent inhibitor 
of Dyrk1a activity in vitro is Leucettine 41 (L41) which is derived from the marine sponge alkaloid 
Leucettamine B (Tahtouh et al., 2012; Debdab et al., 2011).  L41 administered to mouse models 
of Alzheimer’s disease rescues Aβ-induced cognitive impairments (Naert et al., 2015).  However, 
the efficacy of L41 on Dyrk1a activity in vivo has not been reported.  Folding intermediate-
selective inhibitor of Dyrk1a (FINDY) inhibits Dyrk1a activity in vitro by suppressing the 
autophosphorylation of Dyrk1a, thereby inhibiting its catalytic activity.  FINDY rescues 
DYRK1A-induced developmental deformities in Xenopus laevis embryos (Kii et al., 2016).  
Recently, two studies have administered novel Dyrk1a inhibitors to DS mouse models in vivo and 
reported significant improvements.  An ~3 week treatment with the compound 3-(4-fluorophenyl)-
5-(3,4-dihydroxyphenyl)-1H-pyrrolo[2,3-b]pyridine, 5a) (F-DANDY) via a 20mg/kg daily IP 
injection significantly improved MWM performance in adult Ts65Dn mice (age not specified), 
although trisomic (Ts) mice treated with this molecule were still significantly impaired versus 
euploid (Eu) controls.  This study could not directly say if F-DANDY was directly inhibiting 
Dyrk1a activity, but quantifiable levels of F-DANDY were observed in the brain, suggesting that 
it is able to cross the blood-brain barrier (Neumann et al., 2018).   
Another study administered the molecule ALGERNON (alternate generation of neurons) 
both pre-and postnatally to Ts1Cje mice, a mouse model of DS that triplicates fewer Mmu16 genes 
than Ts65Dn mice but still includes three copies of Dyrk1a (Nakano-Kobayashi et al., 2017).  
Normalization of the number of BrdU+ and BrdU+/DCX labeled cells in the DG  was achieved 
when 9-week-old Ts1Cje were administered ALGERNON via SC for 12 consecutive days, as well 
as when mice were administered 10mg/kg SC for 10 consecutive days.  Next, the study 
13 
 
administered ALGERNON to pregnant dams from E10-E15 and found that treatment normalized 
cortical layer thickness in E15.5 embryos.  Mice treated with ALGERNON prenatally showed 
improvements in several hippocampal–dependent tasks including the Barnes maze and contextual 
fear conditioning when tested as adults.  However, this prenatal treatment did not significantly 
improve BrdU+ cell proliferation observed in adult Ts1Cje mice.  ALGERNON does not inhibit 
MAO-A activity and its rescuing effects at both embryonic and adult ages warrant further 
investigation.   
Despite the promising preclinical studies using new Dyrk1a inhibitors like ALGERNON 
and F-DANDY, there is a lack of Dyrk1a inhibitors that have been administered in a clinical 
setting.  Because a common goal is to effectively translate therapeutics to individuals with DS, it 
is critical that novel Dyrk1a inhibitors pass safety and efficacy studies in both preclinical and 
clinical settings.  The development and screening of small molecule kinase inhibitors is not unique 
to DS, as a number of diseases, such as cancer, are linked to alterations in protein kinase signaling 
(Noble et al., 2004).  For example, casein kinase II (CK2) is a serine/threonine kinase that plays 
an important role in controlling cell growth, proliferation and survival (Trembley et al., 2010; 
Ruzzene et al., 2010).  The overexpression of CK2 is seen in several types of cancers, including 
breast, kidney and lung, and the inhibition of CK2 kinase activity is a target for cancer drug therapy 
(Ferguson et al., 2011).  Many CK2 inhibitors inhibit other kinases, including proto-oncogene 
serine/threonine-protein kinases (PIMs) and dual-specificity tyrosine-regulated kinases (DYRKs), 
due to their phylogenetic similarity (Aranda et al., 2011; Pagano et al., 2008) (Debdab et al., 2011).  
Similar to Dyrk1a, CK2 is constitutively active and does not require phosphorylation by other 
kinases for activation.  The recent overlap in CK2 and Dyrk1a inhibition by several small molecule 
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inhibitors opens the possibility for using these kinase inhibitors as targeted Dyrk1a inhibitors to 
improve DS-related deficits. 
1.9 Justification of using CX-4945 
The current study utilized the CK2 and Dyrk1a inhibitor CX-4945, [5-(3-
chlorophenylamino)benzo[c][2,6]naphthyridine-8-carboxylic acid] (Pierre et al., 2011; Siddiqui-
Jain et al., 2010) for several reasons.  Docking studies show that CX-4945 inhibits DYRK1A 
activity by binding to the ATP-binding pocket with a high degree of potency and with significantly 
higher half maximal inhibitory concentration values (IC50) than well-known Dyrk1a inhibitors 
including harmine, INDY, and proINDY (Kim et al., 2016; Ferguson et al., 2011).  CX-4945 
exhibits a half-life of ~10 hours and an oral bioavailability of ~79% in rats following a single 
10mg/kg oral gavage (CX-4945 dissolved in a mixture of DMSO/PEG400/distilled water, 0.5: 4: 
5.5)  (Son et al., 2013).  These findings are in stark contrast to EGCG, which degrades in solution, 
is rapidly metabolized upon ingestion, is rapidly excreted once metabolized, and is almost 
undetectable in human serum 8 hours after a 200mg dose (Chow et al., 2003; Lee et al., 2002; 
Chen et al., 1997; Chow et al., 2001).  However, CX-4945 has only recently been administered 
with the goal of rescuing Dyrk1a-mediated tau hyperphosphorylation (Stringer et al., 2017).  
Dyrk1a is hypothesized to mediate the hyperphosphorylation of Tau at the Thr-212 residue 
in the hippocampus and frontal cortex of transgenic Dyrk1a (TgDyrk1a) mice (Ryoo et al., 2007).  
This phenotype is also seen in 293T cells that overexpress DYRK1A, and when CX-4945 was 
administered in vitro, a significant reduction in Tau hyperphosphorylation at T212 was observed 
(Kim et al., 2016).  The administration of CX-4945 was also shown to reverse Dyrk1a-mediated 
deficits in the translocation of NFAT-C, a critical transcription factor that mediates signaling 
pathways critical for vertebrae development (Nguyen et al., 2008).  The shuttling of NFAT-C 
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inside the nucleus (where it can carry out transcriptional activity) has been shown to be dependent 
on levels of DYRK1A (Arron et al., 2006; Kurabayashi et al., 2013).  In vivo, a single dose of 
75mg/kg CX-4945 (dissolved in phosphate-buffered saline (PBS) and DMSO, amounts not 
described) to BACTgDyrk1a mice significantly decreased the Tau T212 hyperphosphorylation 
levels in the hippocampus at 30 minutes and 1 hour post administration (Kim et al., 2016). 
A second factor in selecting CX-4945 is its expanding in vivo use beyond the recent 
transgenic DYRK1A mouse model study (Kim et al., 2016).  The application of CX-4945 has 
primarily focused on animal models of cancer as an effective inhibitor of CK2, which is 
significantly elevated in cancerous tumors.  However, the administration of CX-4945 across 
several studies helps establish its safety if it were to be repurposed in another mouse model.  For 
example, CX-4945 (25mM dissolved in NaH2PO4 buffer) administered via oral gavage at 25, 50 
and 75mg/kg twice a day for 35 consecutive days to ~8 week old nu/nu mice had no significant 
effect on body weight (Pierre et al., 2011).  A separate study also reported no significant weight 
changes in 5-7 week old female CrTac:Ncr-Foxn1nu mice who received 25mg/kg or 75mg/kg CX-
4945 (5mM dissolved in unknown amount of DMSO) twice a day for 30 consecutive days.  
(Siddiqui-Jain et al., 2010).  While weight was not directly reported, ~3-4 month old NRGS 
(NOD-Rag1null IL2Rgammanull) mice were treated with 75mg/kg CX-4945 via oral gavage 
twice daily for 18 consecutive days (Ribeiro et al., 2017).  In addition, 7 week old C57BL/6NTac 
mice received a twice daily IP injection of 25mg/kg CX-4945 (5mM dissolved in an unknown 
amount of DMSO) for 6 consecutive days (Rossi et al., 2015).  The safety and efficacy of CX-
4945 administration in cancerous mouse models has led CX-4945 to undergo testing in Phase1b 
and Phase 2 clinical trials (Marschke et al., 2011)(ClinicalTrials ID: NCT02128282).  The 
demonstration of safety and efficacy of CX-4945 administration across various mouse models, its 
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long half-life, and its effect on Dyrk1a-mediated deficits in vitro warrant further investigation in 
mouse models of DS. 
With the exception of the two previously mentioned studies published in the last six months 
(ALGERNON and F-DANDY), there is a lack of studies administering novel Dyrk1a inhibitors to 
mouse models of DS.  Along with the Dyrk1a inhibitors mentioned here, there have been over a 
dozen novel Dyrk1a inhibitors that have been patented in recent years (Nguyen et al., 2017).   
However, there seems to be a high level of disconnect between the establishment of a Dyrk1a 
inhibitor in vitro and its application and efficacy in DS mouse models in vivo.  Despite its 
established safety in humans and efficacy in the previously mentioned mouse models, CX-4945 
has not been administered to Ts65Dn mice.  Furthermore, developmental, behavioral and 
histological phenotypes post-CX-4945 treatment have not been reported in any mouse model.  
Therefore, the administration of a novel Dyrk1a inhibitor to Ts65Dn mice during a time of elevated 
Dyrk1a expression would significantly contribute to the DS research field. 
1.10 Introduction of specific aims 
To date, the majority of therapeutics tested in DS mouse models have been administered 
at adult ages.  However, several studies that have administered therapeutics during embryonic, 
neonatal or perinatal ages, have reported significant improvements in developmental, behavioral 
and histological deficits [for review see (Stagni et al., 2015)].  In parallel with these findings, there 
is a significant push from DS researchers and clinicians to start interventions/therapeutics earlier 
in development (Stagni et al., 2015; Edgin et al., 2015).  Alterations in the transcriptome of a 
developing DS brain have been observed in tissue as early as 14 weeks post conception and there 
are significant levels of variation in gene expression between ages and brain regions (Olmos-
Serrano et al., 2016).  For example, the number of differentially expressed genes in the dorsal 
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frontal cortex appears to increase with age, but the number of differentially expressed genes in the 
cerebellar cortex appear to remain stable over the life span of an individual with DS (Olmos-
Serrano et al., 2016).  If the goal is to target Dyrk1a and its corresponding phenotypes, identifying 
its temporal and spatial expression patterns in brain regions that influence specific phenotypes is 
an important first step.   
Thus, the first goal of this study was to bridge this gap by first establishing the temporal 
and spatial expression levels of Dyrk1a protein in regions critical for behavioral and anatomical 
phenotypes in perinatal and adolescent Ts65Dn mice.   
1. Specific Aim 1 (SA1): Measure Dyrk1a protein levels in the cerebellum, hippocampus 
and cerebral cortex of euploid (control) and Ts65Dn (3 copies of Dyrk1a) male mice at 
five distinct postnatal ages.  Based on previous evidence suggesting the Dyrk1a 
expression is elevated during neo- and perinatal ages, it was hypothesized that Dyrk1a 
protein levels would be elevated at perinatal ages (PD12, PD15, PD18) in trisomic mice, 
but not at late adolescence (P24, P30) and early adulthood (P42). 
Once the temporal and spatial profile of elevated Dyrk1a protein levels were established in 
Ts65Dn mice, the second goal of the study was to administer CX-4945 during the identified period 
of elevation, and to determine the efficacy of CX-4945 treatment on developmental, behavioral 
and histological deficits in preweaning Ts65Dn mice.   
2. Specific Aim 2 (SA2) Administer 75mg/kg of CX-4945 and/or 10% DMSO vehicle at a 
time when Dyrk1a protein is elevated, in order to assess its effects on 
neurodevelopmental behavior and dentate gyrus cell proliferation in Ts65Dn and euploid 
mice.  It was hypothesized that treating trisomic mice with a Dyrk1a inhibitor at a 
specific age when Dyrk1a protein is elevated would result in improvements in locomotor 
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activity and the homing task.  In addition, it was hypothesized that the targeting inhibition 
of Dyrk1a with CX-4945 would significantly improve the deficits in cell proliferation in 
the dentate gyrus of the hippocampal formation in trisomic mice. 
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CHAPTER 2. METHODS  
2.1 Mating schemes 
There were mating schemes used to generate mice used for both SA1 and SA2.  At the start 
of this project, efforts were currently underway to generate Ts65Dn mice that carried a floxed 
allele of Dyrk1a for use in a future study (designated Ts65Dn.Dyrk1afl/+).  These mice had very 
similar breeding backgrounds to the traditional Ts65Dn mice that have been extensively used in 
our laboratory (Stringer et al., 2015; Stringer et al., 2017).  Presumably, the only significant 
difference between Ts65Dn.Dyrk1afl/+ and the Ts65Dn mice was the presence of a single floxed 
Dyrk1a allele.  The allele containing the lox-P sites was presumably active, and without the 
presence of Cre-recombinase it was assumed that the offspring of both (Ts65Dn x B6C3F1) and 
(Ts65Dn x B6C3.Dyrk1afl/fl) matings would yield identical outcomes.  In addition, Ts65Dn mice 
are difficult to breed (Roper et al., 2006) and it was hypothesized that the use of offspring from 
(Ts65Dn x B6C3.Dyrk1afl/fl) matings would allow for an adequate production of mice. 
Trisomic and euploid mice were obtained from two mating schemes.  Ts65Dn and euploid 
mice were created by crossing Ts65Dn females (approximately 50% B6 and 50% C3H background 
with small trisomic marker chromosome) with B6C3F1 males.  Ts65Dn and B6C3F1 mice are kept 
in the lab for approximately 10 months.  New Ts65Dn, B6C3F1, B6 AND C3H mice are purchased 
from the Jackson Laboratory (Bar Harbor, ME) every six months and these new mice, as well as 
the mice generated within our colony, are used to generate Ts65Dn mice.  Ts65Dn females were 
used as breeders for colony maintenance, as male Ts65Dn mice are sub-fertile.  Thus, in both SA1 
and SA2 only male Ts65Dn and euploid mice were used.  
20 
 
The second breeding scheme used to produce trisomic and euploid mice involved 
crossing female Ts65Dn with male B6C3.Dyrk1a fl/fl (F6-F8) mice.  As part of a developing 
study, our laboratory received B6.Dyrk1afl/fl+ mice from Northwestern University, which 
contained one floxed Dyrk1a allele (Thompson et al., 2015).  A schematic detailing the 
production and mating of these mice is seen in Figure 1.  These B6.Dyrk1afl/fl mice were 
backcrossed to C3H/HeJ mice, producing B6C3.Dyrk1a fl/+ mice that had a ~50% B6 and ~50% 
C3H background.  These B6C3.Dyrk1a fl/+ mice were intercrossed with B6C3.Dyrk1a fl/+ 
siblings, resulting in B6C3.Dyrk1a mice that were either floxed at both Dyrk1a alleles 
(B6C3.Dyrk1a fl/fl), one allele (B6C3.Dyrk1a fl/+) or neither allele (B6C3.Dyrk1a +/+).  Mice that 
were floxed at both Dyrk1a alleles (B6C3.Dyrk1a fl/fl) were intercrossed with other B6C3.Dyrk1a 
fl/fl siblings until the sixth-eighth filial (F6-F8) generation was reached.  Once this generation was 
reached (F7 in Figure 1), B6C3.Dyrk1afl/fl males were bred with female Ts65Dn mice.  From this 
mating, the current study utilized the male euploid and trisomic mice that had one floxed Dyrk1a 
allele, from here on after referred to as euploid or trisomic Dyrk1a fl/+ mice (bolded in Figure 1).   
Near the end of SA2, it became obvious that the offspring from the two breeding schemes 
were in fact yielding different outcomes.  However, the majority of mice used for both SA1 and 
SA2 were from (Ts65Dn x B6C3.Dyrk1afl/fl) matings, and there were too few mice from 
(Ts65Dn x B6C3F1) matings for meaningful statistical conclusions to be drawn.  Therefore, the 
primary data reported in this study are from euploid and trisomic mice from (Ts65Dn x 
B6C3.Dyrk1afl/fl) matings, whereas data from the euploid and trisomic mice from (Ts65Dn x 
B6C3F1) matings are located in the appendix.  
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Figure 1.  Breeding schematic for the offspring from (Ts65Dn x B6C3.Dyrk1afl/fl+) matings. 
 
2.2 Ts65Dn PCR 
Offspring from both (Ts65Dn x B6C3F1) and (Ts65Dn x B6C3F1.Dyrk1afl/fl) matings 
used in this study were genotyped using the breakpoint PCR (Reinholdt et al., 2011).  For 
euploid and trisomic Ts65Dn mice, the breakpoint PCR makes use of a forward (Chromosome 
17) (GTGGCAAGAGACTCAAATTCAAC) and a reverse (Chromosome 16) primer 
(TGGCTTATTATTATCAGGGCATTT) set to amplify a ~275 bp product at the translocation 
point on 1716 murine chromosome and a positive control primer set of IMR1781 
(TGTCTGAAGGGCAATGACTG) and IMR1782 (GCTGATCCGTGGCATCTATT) that 
amplifies a 544bp product (primers from Invitrogen).  The final PCR mix contained MyTaq 
reaction buffer (1x final), MyTaq polymerase (2.5U/μl final) (Bioline Taunton, MA), water, the 
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two sets of primers (0.4μM final) (Bioline), and DNA (100ng/rxn).  The PCR cycling conditions 
were set to 94°C for 2 minutes to initialize the reaction, followed immediately by 45 seconds at 
94°C to melt the template DNA in a denaturation step that yields single stranded DNA 
molecules. The template DNA was then cooled to 55°C for 45 seconds to allow annealing of the 
primers to the template, and strand elongation to occur through the action of Taq polymerase at 
72°C for 1 minute. The denaturation, annealing and elongation steps were repeated for 34 cycles 
and were followed by a final elongation step for 7 minutes at 72°C. To verify the PCR products, 
the samples were separated on a 1.5% agarose gel made by dissolving 0.75 g of agarose (Fisher 
Scientific, Geel, Belgium) in 50 mL 1X TAE buffer (40mM tris, 20mM acetic acid, 1mM 
EDTA).  The size(s) of PCR products were determined by comparison with a DNA ladder, 
which contained DNA fragments of known size, run alongside the products on the gel. This is a 
crucial step in our studies as it is important to positively distinguish trisomic Ts65Dn mice from 
the euploid mice.  
2.3 PCR on offspring from (Ts65Dn x B6C3.Dyrk1afl/fl) matings 
Both euploid and trisomic offspring from (Ts65Dn x B6C3.Dyrk1afl/fl) matings 
underwent a separate PCR protocol as previously described (Thompson et al., 2015).  Briefly, 
each 25µL reaction contained 2.5U/μL MyTaq, 1x MyTaq buffer (Bioline), 0.4µM primers 
forward 5’-ATTACCTGGAGAAGAGGGCAAG-3’ and reverse 5’-
TTCTTATGACTGGAATCGTCCC-3’ (Invitrogen), and 16.75µL H2O.  Both the forward and 
reverse primers were used to identify and amplify the presence of loxP sites flanking (floxed) 
located just before exon 5 and spanning exon 6 on Dyrk1a alleles.  The PCR cycling conditions 
were as follows: 95°C for 3 min, 35 cycles of 95°C for 20 s, 60°C for 15 s, and 72°C for 15s, 
followed by a final 1 minute extension at 72°C and 4° for 5 minutes. PCR products were 
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separated on a 1.5% agarose gel. WT amplicons are 503bp and floxed amplicons are 603bp as 
seen in Figure 2. 
 
Figure 2.  PCR Gel image from offspring of (Ts65Dn x B6C3.Dyrk1afl/+) matings. 
The ladder in lane 1 contains the weight marker for 500bp (outlined in red) and 700bp 
(outlined in blue).  Lanes 2, 3, 4 and 6 contain mice heterozygous for one floxed Dyrk1a 
allele.  The animal in lane 5 has both Dyrk1a alleles floxed (band seen at ~603bp) and in 
lane 7 the animal has neither Dyrk1a allele floxed (band seen at ~503bp).  Lane 8 contains 
water as a control. 
 
 
2.4 Determination of genotypic sex by PCR 
Sex was genetically determined by PCR on offspring from (Ts65Dn x B6C3F1) and 
(Ts65Dn x B6C3.Dyrk1afl/fl) matings used in this study (McFarlane et al., 2013). Amplification of 
Sly and Xly genes, which reside on the Y and X chromosome, respectively, was accomplished 
using the following primer pairs: forward 5’-GATGATTTGAGTGGAAATGTGAGGTA-3’; 
reverse 5’-CTTATGTTTATAGGCATGCACCATGTA-3’. Reactions were performed with a final 
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volume of 25μL containing 1x KCl buffer, 1.5mM MgCl2, 0.2mM dNTPs, 0.2μM primers, 19.05 
µL H20, 1 unit Taq polymerase (Bioline) and 100ng DNA using the following PCR specifications: 
denaturation at 94°C for 2 min, followed by 35 cycles at 94°C for 30 s, 57°C for 30 s, 55°C for 30 
s, and 72°C for 30 s, ending with a 72°C final elongation step for 5 min and 4°C for 5 min. Products 
were visualized via electrophoresis on a 2% agarose gel. Amplification using the aforementioned 
primers resulted in a single 280-bp amplicon for males, while female DNA yielded three amplicons 
of 685-, 660-, and 440-bp.  
2.5 Animal care 
All animals were housed in the secure AAALAC-accredited Science Animal Resource 
Center facility in the IUPUI School of Science.  Mice were housed in rooms with a standard 12:12 
light:dark cycle.  Experiments with animals were carried out in accordance with the NIH Guide 
for the Care and Use of Laboratory Animals and received prior approval from the IACUC 
committee at IUPUI. 
2.6 Timeline for SA1 
On postnatal days 12, 15, 18 and 24, male mice were removed from their home cages and 
euthanized using isoflurane followed by cervical dislocation.  Mice used for the late 
adolescent/early adult age groups (P30, P42) were weaned at P21, group-housed in standard mouse 
cages and were euthanized in the same manner at their respective ages.  Following cervical 
dislocation, tissue from the cerebellum, cerebral cortex and hippocampus was rapidly dissected, 
snap frozen, and stored at -80º C.   
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2.7 Isolation of protein from brain tissue and quantification 
Tissue samples were removed from a -80º C freezer and homogenized in RIPA buffer 
(10mM Phosphate Buffer (pH 7.4), [10% Glycerol (Fisher Scientific, Fair Lawn, NJ), 1% NP-40 
(United States Biological, Swampscott, MA) 0.1% SDS (Fisher Scientific, Fair Lawn, NJ), 4mM 
EDTA (Fisher Scientific, Fair lawn, NJ), 0.15M NaCl (Fisher Scientific, Fair Lawn, NJ), 1x 
Protease inhibitor cocktail (Roche Diagnostics, Mannheim, Germany)].  The sample was then 
vortexed at 10,000 rpm for 10 minutes at 4o C.  After the sample was vortexed, the supernatant 
was slowly extracted (to ensure no part of the protein pellet was extracted) and transferred to a 
new centrifuge tube, which was stored at -80º C.  The isolated protein was then quantified using a 
Bradford assay (Bradford, 1976).  
2.8 Western blot to quantify Dyrk1a protein 
Protein levels were first quantified for P30 and P42 male animals, and normalized to actin.  
Isolated protein lysates (20µg) from the three brain regions were resolved electrophoretically on 
polyacrylamide gels (Bolt 4-12% Bis Tris Plus Gels), and then transferred to PVDF 
membranes.  Membranes were blocked in 5% milk in Tris Buffered Saline with 0.1% Tween 20 
(TBS-T), incubated overnight at 4°C in primary antibodies diluted in 5% milk-TBS-T as follows: 
rabbit anti-DYRK1A antibody, 1:500 (A303-802A, Bethyl Laboratories); mouse anti-beta-actin, 
1:5000 (A2228, Sigma Aldrich), and labeled with donkey anti-rabbit IgG AlexaFluor 790 and 
donkey anti-mouse IgG AlexaFluor 680 secondary antibodies (1:10,000, Jackson 
Immunoresearch).  Fluorescence was detected using a LI-COR CLx Imager, and both Dyrk1a and 
actin bands were quantified using Image Studio.   
Dyrk1a protein levels were then quantified in the adolescent and perinatal male mice (P24, 
P18, P15 and P12) and normalized to total protein from Coomassie blue stain.  Using the same 
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primary and secondary antibodies as the P30 and P42 mice, it was observed that multiple bands 
were observed at ~90 kDa, the approximate weight of Dyrk1a.  The first band directly below 
~90kDa is likely the first and second isoforms of Dyrk1a, which are reported to have a weight of 
~86 and ~84kDa.  Subsequent isoforms of Dyrk1a weigh ~66, 60, 59kDa.  The remaining 
observable faint bands do not appear to match the weights of the Dyrk1a isoforms, thus, these 
residual faint are likely due to several methodological variables, including the type of gels and 
membranes used (Abnova, personal communication).  The multiple bands were more pronounced 
at these younger ages, and at the suggestion of a fellow researcher who had encountered a similar 
problem, an alternate primary antibody was used to quantify Dyrk1a protein levels and total protein 
was used as a standard.  With the new antibody, multiple bands were still observed.  It was 
determined that quantifying just the top band or all of the multiple bands produced very similar 
normalized values (correlation >0.8).  The multiple bands were very close to each other, so in order 
to ensure a consistent measurement, all of the bands were boxed together and a single fluorescence 
level from that box was used (see Figure 3a).  The Western blot procedure remained the same as 
previously mentioned, but the antibodies were; mouse anti-DYRK1A antibody, 1:500 (MO1 Clone 
7D10A Abnova), and labeled donkey anti-mouse IgG AlexaFluor 790 secondary antibodies 
(1:10,000, Jackson Immunoresearch). Fluorescence was detected using a LI-COR CLx Imager, 
and Dyrk1a was quantified using Image Studio.  After the membrane was scanned, it was stained 
with Coomassie blue dye (Coomassie Brilliant Blue R-250 [Thermo Fisher] 0.5mg, 250mL 100% 
ethanol, 50mL acetic acid, 200mL H2O) for 2 minutes with gentle agitation.  The dye was then 
drained, and the membrane was gently agitated in a destain solution (500mL 100% ethanol, 400mL 
H20, 100mL acetic acid) for ~20 minutes.  Then, the destain was drained and the membrane sat in 
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water overnight.  After 24 hours, the membrane was scanned using a HP Scanner, and the total 
protein (measured from ~90kDa to ~40kDa) was quantified in Image J.   
For P30 and P42 animals, Dyrk1a fluorescent levels were normalized to fluorescent actin 
levels.  For P12, P15, P18 and P24 animals, fluorescent Dyrk1a levels were normalized to total 
protein levels.  Across all ages, each membrane contained two controls (Euploid) and two Ts65Dn 
mice (Trisomic), with all three brain regions from each mouse (total of 12 samples ran on each 
gel).  Each normalized value was expressed as a ratio relative to the mean intensity value of the 
same region for the two controls that were run in the same blot (see Figure 3a). 
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Figure 3. Representative Western blot from P12 and P30 male mice from (Ts65Dn x 
B6C3.Dyrk1afl/fl) matings  
On the far left on both 3a and 3b is the protein ladder (red lines) to assess the weight of 
specific protein bands.  The values in yellow text below the multiple green bands is the 
measure of Dyrk1a fluorescence.  The values in white text above the green bands represent 
the ratio of Dyrk1a fluorescence: total protein loaded, normalized to the euploids within 
each brain region.   Figure 3a represents two euploid (Eu) and two trisomic (Ts) mice.  
Figure 3b represents a Western blot with P30 males.  The P30 and P42 Western blots also 
included a quantification of Dyrk1a fluorescence bands.  However, in these scans Dyrk1a 
fluorescence levels were normalized to actin levels (seen at ~42kD). 
 
2.9 Statistical analysis 
For the Western blot analysis at a specific age, the normalized ratio from each brain region 
was analyzed using a mixed ANOVA with brain region as a within subjects measure and genotype 
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as a between-group factor.  Fisher’s LSD tests were used for post hoc comparisons to follow up 
significant ANOVA main effects or interactions. At each age, effect sizes were calculated using 
the standardized mean difference of the normalized ratios of a specific brain region between 
euploid and trisomic mice. 
2.10 Identifying appropriate phenotypes to assess in P14-P18 euploid and Ts65Dn mice 
The goal of this study was to determine if treatment with a Dyrk1a inhibitor during a 
specific period of Dyrk1a elevation would significantly improve deficits in trisomic phenotypes.  
For behavioral evaluation, ~P14-P18 mice have fully developed neurodevelopmental reflexes (i.e. 
prehensile reflex, negative geotaxis, righting reflex, startle response, etc.) (Fox, 1965).  Although 
there are few studies that have characterized behaviors and anatomical phenotypes at this age in 
transgenic Dyrk1a (TgDyrk1a) or mouse models of DS, the studies provided the rationale for 
selecting appropriate behaviors to assess.  At P14, TgDyrk1a mice exhibit significant deficits on a 
single homing test, wire suspension test and coat hanger test (Altafaj et al., 2001).  Ts1Cje mice 
exhibited deficits on a two-trial homing test at P12, and Ts65Dn mice exhibited similar homing 
deficits at P12 and hyperactive behavior at P21 (Guedj et al., 2015; Holtzman et al., 1996).  Ts65Dn 
mice exhibit significant decreases in DG cell proliferation at P15 and P18 (Bianchi et al., 2010; 
Contestabile et al., 2007).  In the cerebellum, P14 Ts65Dn mice have significantly decreased 
cerebellar area, internal granule layer thickness, and granule cell density (Roper et al., 2006).  
With a five-day treatment span during a pre-weaning age, special consideration was made 
to select behavioral tests that minimized stress and the length of time mice were removed from the 
home cage.  In addition to daily growth, mice were assessed for motor coordination (locomotor 
activity), exploratory behavior (modified homing test), and hippocampal neurogenesis.  
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2.11 Timeline for SA2 
Each (Ts65Dn x B6C3F1) or (Ts65Dn x B6C3.Dyrk1afl/fl) litter was randomly assigned to 
receive either CX-4945 or vehicle treatment.  In (Ts65Dn x B6C3.Dyrk1afl/fl) litters, all mice (both 
males and females) received the same treatment.  One reason for administering the same treatment 
to the entire litter was that the genotypes and sexes of the mice was not always known at the time 
of treatment.  By treating the entire litter, this helped ensure that group sizes remained balanced 
across treatment groups.  The exception to this was in offspring from (Ts65Dn x B6C3F1) litters, 
as only the males received treatment.  The females were necessary for colony growth as they are 
an integral part of the breeding colony.  However, all mice (both males and females) from (Ts65Dn 
x B6C3F1) or (Ts65Dn x B6C3.Dyrk1afl/fl) litters were weighed daily, even females from (Ts65Dn 
x B6C3F1) matings.  Both males and females from (Ts65Dn x B6C3.Dyrk1afl/fl) matings were 
treated and underwent behavioral testing, however, on data on the male mice are reported here.  A 
schematic of the treatment and behavioral timeline is seen in Figure 4.  In SA1, an elevation in 
Dyrk1a protein at P15 was observed in male Ts65Dn.Dyrk1afl/+ mice.  Therefore, the treatment 
began just before the onset of significant elevation, P14, and ended when the elevation was no 
longer significant, at P18.  On P14-15, mice received the single daily subcutaneous (SC) injection 
of their litter-assigned treatment.  There were two behavioral tasks used in this behavioral 
paradigm; the homing and locomotor activity task.  Each of these tasks was administered once to 
an entire litter, and the order of these tasks (P16 or P17) was counterbalanced across litters.  On 
P16, mice received the treatment injection, and approximately 30 minutes later, underwent 
behavioral testing in either the locomotor activity or homing test.  This procedure was repeated on 
P17, with the second behavioral task (either homing or locomotor activity, depending on 
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counterbalanced order).  On P18 mice received their final treatment injection along with a single 
BrdU injection (100mg/kg) and were sacrificed two hours later. 
 
 
 
 
 
 
Figure 4.  Behavioral timeline for SA2. 
 
 
2.12 Treatment preparation and delivery 
CX-4945 was obtained from SignalChem (400mg of CX-4945, received 10/31/17; MW: 
349.77g/mol).  A 250mM solution was made by vigorously vortexing 24.5mg CX-4945 with 
280μL DMSO in a 1.5mL microcentrifuge tube at room temperature. The treatment suspension 
was prepared by combining 60μL 250mM CX-4945 with 540μL PBS in a separate 1.5mL 
microcentrifuge tube. The suspension was vortexed vigorously and stored at -20°C.  The 10% 
DMSO was also aliquoted into microcentrifuge tubes and stored at -20°C.  On the day of treatment, 
tubes were removed from the freezer, warmed to 37o C, and vortexed.  Starting on PD14, litters 
were randomly assigned to one of two treatments; 75mg/kg CX-4945 or volume-matched 10% 
DMSO.  Each animal due to receive treatment was removed from its cage and weighed.  The 
appropriate amount of treatment was delivered SC using a new 28-gauge disposable needle for 
each mouse.  After the injection, the animal was placed in a holding cage while the other mice in 
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the same cage were weighed and treated, if necessary.  After all mice had been treated, they were 
transferred from the holding cage to their home cage. 
2.13 Locomotor activity 
Approximately 30 minutes post-injection, the entire cage (including parents and any 
untreated mice) was removed from the colony room, covered with a navy cloth and transferred to 
the Open Field testing room.  Mice acclimated to the room for ~5 minutes while the experimenter 
started the computer and set up the test chambers for testing.  Each mouse was placed in a 
Versamax Animal Activity Monitor (Accuscan Instruments, Columbus, OH) for 10 minutes. 
Activity was recorded by intersecting infrared photocell beams (2 cm above the chamber floor) 
evenly spaced along the walls of the 40×40 cm test chamber. Sound attenuating box chambers 
(inside dimensions, 53 cm across × 58 cm deep × 43 cm high) equipped with a house light and fan 
for ventilation and background noise encased the test chamber. For this study, the house light was 
turned on. The chambers are attached to a Dell computer which recorded accumulated activity 
counts every minute. Following the end of the session, the chambers were cleaned with 20% 
ethanol and animals were returned to their home cage in the colony room.  
2.14 Homing task 
The homing task is based on a mouse’s development to orientate itself towards their home 
cage once removed.  The task was first utilized by Altman and Sudarshan who demonstrated that 
rats would orientate themselves and begin crawling toward their home cage and littermates when 
removed from the home cage (Altman et al., 1975).  A common homing task design is to remove 
pups from their home cage and mother for approximately 30 minutes.  They are then placed in a 
new cage, opposite of the end in which home cage bedding covers 1/3 of the floor.  The time it 
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takes the mouse to reach the home bedding is recorded.  Depending on the task procedure and the 
age of the animal, this task can assess locomotion, olfaction and/or exploratory behavior.  This 
task has been extensively used in animal models of prenatal malnutrition, drug exposure, and 
neurodevelopmental disorders to assess postnatal sensorimotor development (Pometlová et al., 
2009; Lim et al., 2008; Tonkiss et al., 1996; Holtzman et al., 1996; Mikulecká et al., 2014).  The 
current study used a modified homing task (Tonkiss et al., 1996) in order to assess pre-weaning 
locomotion and exploratory behavior in Ts65Dn mice.   
Approximately 15 minutes post injection, all pups in the litter were transferred to a clean 
cage containing fresh bedding and a cardboard igloo.  The cage was covered with a navy cloth and 
brought to the homing test testing room.  The cloth was removed, and the animals were left to 
habituate to the testing room for approximately 20 minutes undisturbed.  The lighting for the 
testing room was approximately 60 lux.  The homing test apparatus was a standard clean mouse 
cage (25.4 x 16.5 x 12 cm) containing two plastic lids (7cm in diameter) placed in opposite corners 
3cm from the wall.  The lids contained bedding from the home cage, or new bedding.  The location 
of the lids was counterbalanced across animals.  Trials were recorded with video tracking using 
ANYMAZE Software (Stoelting Co., Wood Dale, IL).  A mouse was removed from the transfer 
cage and placed in a new holding cage that was placed next to the homing apparatus.  The lids 
were placed in their respective pre-determined location, and the mouse was removed from the 
holding cage and placed next to the apparatus wall, facing towards the center.  The mouse was 
allowed to explore for 60 seconds, then it was removed and placed in the adjacent holding cage.  
The lids were removed, wiped with 20% ethanol and their locations were reversed.  The entire 
apparatus was cleaned with 20% ethanol.  The inter-trial interval was approximately 60 seconds.  
Once cleaned, the mouse was returned to the apparatus for the second trial and allowed to explore 
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for 60 seconds.  Once the second trial ended, the mouse was removed and placed back in the 
transfer cage with the other pups.  The lids were removed, and the bedding used for the previous 
animal was discarded.  The lids and apparatus were wiped with 20% ethanol, the lids were once 
again filled with home cage bedding or new bedding and were placed in the respective location for 
the next mouse. 
2.15 Bromo-2-hydroxyuridine preparation and brain extraction 
5-Bromo-2-hydroxyuridine (BrdU; B5002 Sigma) was stored at -20° C until the day of 
treatment.  BrdU was removed from the freezer, weighed on analytical scale, added to a 2ml tube, 
and heated (50° C) 0.9% sterile saline solution was slowly added via syringe to yield a final 
concentration of 10mg/mL.  The solution was gently vortexed and was used immediately for 
injections.  On PD18, the animal received a single IP injection of 100 mg/kg of BrdU (10mg/ml 
concentration in 0.9% sterile saline, approximately 10mg/kg injection volume).  This injection was 
given immediately after the final treatment injection was delivered. 
Two hours later, mice were euthanized using isoflurane followed by cervical dislocation.  
Brains were carefully removed from the skull and placed in 4% paraformaldehyde for 24 hours.  
The next day brains were embedded in gelatin block and fixed with 4% paraformaldehyde (PFA) 
for at least 72 hours 40-µm-thick coronal sections were cut on a free floating vibratome (Leica 
Microsystems VT1000) for immunohistochemistry procedures.  Each brain was sectioned 
throughout the extent of the hippocampal formation.  Each brain produced approximately 60 
coronal sections throughout the hippocampal formation, and all of these slices were stored at -80o 
C in a cryoprotectant solution containing glycerol and ethylene glycol in Tris-buffer solution for 
48 hours.   
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2.16 Immunohistochemistry 
A one in five random sampling ratio was used to select slices for peroxidase 
immunohistochemistry to label BrdU+ cells.  For each brain, this sampling ratio yielded 10-12 
sections that underwent immunohistochemical processing.  For the peroxidase 
immunohistochemistry, sections were washed in TBS (0.15 M NaCl and 0.1M Trizma HCl) and 
treated with 3% H2O2 in water for 10 minutes to block endogenous peroxidases.  Then, the slices 
were washed 5x2 min in TBS, and underwent a 30-minute incubation in 2N HCl at 37ºC.  Sections 
were then washed in 0.1M Boric acid (pH=8.6) in TBS, in TBS alone, incubated for 1 hour in 
blocking solution (0.5% Triton X-100 and 3% normal goat serum in TBS), and then incubated 
with the primary antibody solution (rat anti-BrdU, 1:500; Accurate Chemical, OBT0030) for 48 
hours at 4ºC.  Following primary antibody incubation, sections were washed in the blocking 
solution, followed by a 1-hour incubation in the blocking solution.  The slices were then washed 
3 times in TBS and were incubated in the secondary antibody (biotinylated anti-rat made in goat, 
1:250; Vector Laboratories, BA-9400), then for 1 hour in avidin-biotin-peroxidase complex 
solution (ABC Elite Kit; Vector Laboratories, PK-4000) with nickel-enhanced diaminobenzidine 
as the chromagen.  Slices were mounted to chrome-alum subbed slides and allowed to dry for 48 
hours.   
2.17 Tissue staining and counting 
Slides were briefly dipped in milli-q water, and then placed in a 0.5% Methyl green solution 
(Sigma-Aldrich) for 2 minutes.  This was followed by 5 slow dips in water.  Slides were then 
placed in 70% ethanol for approximately 2 minutes, with slices being monitored for differentiation.  
This was followed by a 5 second dip in 95% ethanol, then a 1-minute dip in 100% ethanol.  Finally, 
slides were left in xylene for 5 minutes, and then the counterstained slides were coverslipped with 
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Permount.  Slides were left to dry for 48 hours.  All tissue slices that were processed and mounted 
underwent quantification of BrdU+ cells.  BrdU+ labeled cells were counted throughout the 
subgranular layer of the DG on all sections with a bright-field microscopy camera (Nikon Eclipse 
80i), at 1000x magnitude with the 100x oil objective, using a modified optical fractionator 
approach similar to a previous study (Malberg et al., 2000).  Since only a fraction of slices (1 in 5 
were used) were used for counting BrdU+ labeled cells, the total number of cells for a specific 
slice was calculated with the following equation: 
Total estimated number of cells per slice throughout DG = [(total number of cells counted) 
÷ (number of slices counted)] * 5 (section sampling fraction) 
The volume (area per point: 4000µ2) of the granule cell layer was quantified using the 4x 
objective, using Cavalieri’s principle (Stereologer system and software; Systems Planning and 
Analysis, Inc., Alexandria, VA).   Section thickness was measured optically at 1000x 
magnification using z-axis microcator attached to the microscope stage.  The total volume of the 
granule cell layer was calculated using the following formula: 
Total estimated granule cell layer volume= (average slice thickness) * (area [calculated 
using 4000 u2 disectors]) x 5 (section sampling fraction) 
The density of BrdU+ cells in the DG granule cell layer for each animal was calculated by 
dividing the total number labeled cell counts by the total volume of the granule cell layer. 
2.18 Statistical analysis 
The body weights across treatment days were analyzed using a mixed ANOVA with day 
as a within subjects measure and genotype and treatment as between group factors.  The total 
distance traveled in the locomotor activity test was summed across the entire session and analyzed 
with a two-way ANOVA using genotype and treatment as a between-subjects factor.  The homing 
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test included several measures for both trial 1 and trial 2: total time spent exploring both zones, 
time exploring home zone, time exploring new zone, number of midline crossings, number of 
home zone visits, number of new zone visits, time taken to first explore home zone, time taken to 
first explore new zone, and % of exploration time spent in home zone.  These measures were 
assessed separately for each trial using a two-way ANOVA with genotype and treatment as a 
between-subjects factor.  For the immunohistochemistry analyses, total BrdU+ cell counts, total 
granule cell layer volume, slice thickness, number of slices, and cell density were all analyzed 
using a two-way ANOVA using genotype and treatment as a between-subjects factor.   
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CHAPTER 3. RESULTS  
3.1 (Ts65Dn x B6C3F1) vs (Ts65Dn x B6C3.Dyrk1afl/fl) offspring 
As previously mentioned, two breeding schemes of mice were used in the current study 
(Ts65Dn x B6C3F1) and (Ts65Dn x B6C3F1.Dyrk1afl/fl) to generate trisomic and euploid mice, 
and only results from male mice were reported in the current study.  Table 1 details the background 
of male mice used for the Dyrk1a protein analysis in SA1.  Only euploid and trisomic Dyrk1afl/+ 
male mice were used at P12, P15, and P18.  At P24, P30 and P42 a mix of male offspring from 
both (Ts65Dn x B6C3F1) and (Ts65Dn x B6C3.Dyrk1afl/+) matings were used for Western blot 
analysis.  However, the SA1 results reported here will solely focus on the Western blot analysis 
with euploid and trisomic Dyrk1afl/+ male mice.  The Western blot analysis of male mice from 
(Ts65Dn x B6C3F1) matings are reported in the Appendix. 
 
Table 1.  The distribution of male mice from (Ts65Dn x B6C3F1) and (Ts65Dn x 
B6C3.Dyrk1afl/fl) matings used for SA1.   
Age
Euploid Trisomic Euploid Trisomic
P12 0 0 7 8
P15 0 0 6 7
P18 0 0 7 8
P24 4 4 3 3
P30 1 1 5 5
P42 1 3 3 1
(Ts65Dn x B6C3F1) (Ts65Dn x B6C3.Dyrk1afl/fl)
Background stock distribution of animals used for SA1
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In SA2, males from 11 (Ts65Dn x B6C3.Dyrk1afl/fl) litters and 6 (Ts65Dn x B6C3F1) 
litters were tested.  Table 2 summarizes the litter demographics from these two breeding schemes, 
however, the behavioral outcomes from SA2 are of male mice from (Ts65Dn x B6C3.Dyrk1afl/fl) 
litters.  SA2 outcomes of male mice from (Ts65Dn x B6C3F1) litters are reported in the Appendix.   
There were no significant differences on the average litter size, the number of trisomic mice 
produced within a litter, nor were there any differences in the proportion of trisomic mice produced 
within a litter (see Table 2).  However, there was a non-significant trend towards (Ts65Dn x 
B6C3.Dyrk1afl/fl) matings producing a significantly lower proportion of trisomic males versus 
(Ts65Dn x B6C3F1) matings (p=0.07). 
 
Table 2.  Demographics of offspring from (Ts65Dn.B6C3.Dyrk1afl/fl) and (Ts65Dn x B6C3F1) 
litters for SA2.   
Data includes both male and females.  Data are represented as mean ± SEM. 
 
Females Males Collapsed Females Male Collapsed
1.83±0.79 3.6±0.84 5.5±1.08 2.00±0.33 3.09±0.60 5.09±0.53
0.66±0.33 2.5±0.56 3.1±0.47 1.09±0.28 1.45±0.51 2.45±0.57
11.66±5.69 51.11±11.11 62.77±7.95 23.73±7.72 24.74±8.08 48.48±8.90
Mice per litter
Average number of 
trisomic mice per 
litter
Average proportion 
(%) of trisomic mice 
per litter at P14
(Ts65Dn x B6C3F1)  (6 litters) (Ts65Dn x B6C3.Dyrk1afl/fl)(11 litters)
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Offspring from both (Ts65Dn x B6C3F1) and (Ts65Dn x B6C3.Dyrk1afl/fl) matings were 
used in SA2.  However, the majority of mice used for SA2 were euploid and trisomics from 
(Ts65Dn x B6C3.Dyrk1afl/fl) matings (see Table 3) and the primary analysis presented here will 
utilize only the male euploid and trisomic mice from (Ts65Dn x B6C3.Dyrk1afl/fl) matings.  
Data from mice of both mating schemes (Ts65Dn x B6C3F1) and (Ts65Dn x 
B6C3.Dyrk1afl/fl), as well as mice from just the (Ts65Dn x B6C3F1) litters are reported in the 
Appendix.  During SA2 we observed that the offspring of (Ts65Dn x B6C3.Dyrk1afl/fl) matings, 
particularly trisomic mice, appeared to weigh more than trisomic offspring from (Ts65Dn x 
B6C3F1) matings (see Figure 5).  When analyzing locomotor activity in trisomic mice, weight had 
a significant effect on the total distance travelled in the locomotor test.  The total distance traveled 
in the locomotor activity test was collapsed across DMSO and CX-4945 treatments and segregated 
into whether a mouse weighed under or over 5.4 grams at the time of testing (Figure 6).  This 
analysis highlighted two important findings; 1) there was a greater proportion of  Ts65Dn mice 
that weighed under 5.4 grams than Ts65Dn.Dyrk1afl/+ mice, and 2) of the 2 Ts65Dn.Dyrk1afl/+ 
mice that did weigh under 5.4 grams, their locomotor activity performance was not significantly 
altered by their low weight.  In stark comparison, Ts65Dn mice that weighed under 5.4 grams had 
significant deficits in locomotor activity, regardless of which treatment they received. 
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Table 3.  Distribution of male offspring from (Ts65Dn x B6C3F1) and (Ts65Dn x B6C3.Dyrk1a) 
litters for SA2.   
The majority of animals used for SA2 were offspring from (Ts65Dn x B6C3.Dyrk1afl/fl) 
matings. 
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Figure 5.  Weight progression of offspring from (Ts65Dn x B6C3F1) and (Ts65Dn x 
B6C3.Dyrk1a) matings. 
5a depicts the average weight progression of eupoid mice from the two different mating 
schemes used in the current study.  5b depicts the progression of the trisomic mice from 
the two different mating schemes.  Both 5a and 5b are collapsed across treatment groups.  
Data are represented as mean ± SEM. 
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These findings and the primary use of euploid and trisomic Dyrk1afl/+ in SA1 resulted in 
the current study to analyze and subsequently report euploid and trisomic Dyrk1afl/+ outcomes.  All 
data from this point on represents the offspring from (Ts65Dn x B6C3.Dyrk1afl/fl) matings.  There 
was not sufficient statistical power to draw meaningful statistical conclusions about offspring from 
a (Ts65Dn x B6C3F1) matings.  The data of male mice from the (Ts65Dn x B6C3F1) matings are 
presented separately in the Appendix, along with analysis of data combined across mating 
schemes.   
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Figure 6.  Locomotor activity of trisomic mice from (Ts65Dn x B6C3F1) and (Ts65Dn x 
B6C3.Dyrk1afl/fl) matings based on body weight 
Male trisomic mice were grouped by their weight (under or over 5.4 grams) at the time of 
locomotor testing.  Pink represent Ts65Dn trisomic mice, and the blue depicts 
Ts65Dn.Dyrk1afl/+ mice. 
 
3.2 Aim 1: Dyrk1a Protein Levels at five distinct postnatal ages 
3.2.1 Dyrk1a protein levels at P12 
There was a trend for trisomic Ts65Dn mice exhibiting higher levels of Dyrk1a than 
euploid controls across all three brain regions (p=0.08).  As seen in Table 4, there were no 
significant main or interactive effects of genotype in Dyrk1a protein levels at P12 in male Ts65Dn 
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mice in the cerebral cortex [t(13)= -0.855, p=0.408, d=0.44]; the cerebellum [t(13)= -1.196, 
p=0.253, d=0.62] or the hippocampus [t(13)= -1.658, p=0.121, d=0.82].  There were no 
significant correlations between Dyrk1a protein levels across brain regions.  
 
Table 4.  Protein levels at six distinct postnatal ages in euploid (Eu) and trisomic (Ts) mice from 
(Ts65Dn x B6C3.Dyrk1afl/fl) matings   
Both 4a and 4b represent euploid and trisomic Dyrk1afl/+ mice from (Ts65Dn x 
B6C3.Dyrk1afl/fl) matings.  Ts values within a brain region represent the mean Dyrk1a 
protein levels normalized to euploid levels.  Data are represented as mean ± SEM.  Ts male 
mice exhibited significantly elevated Dyrk1a protein levels across all tissues measured at 
P15, as indicated by the (*).  4a depicts perinatal and adolescent mice that underwent 
Western blots using the Abnova 7D10 Dyrk1a antibody and total protein load as a 
normalization.  The respective effect size for each of the brain regions within an age are 
listed.  Table 4b depicts the young adult and adult mice that were ran on a Western blot 
using the Bethyl A303-802A Dyrk1a antibody.  The effect size for P30 brain regions is 
listed, however, at P42 there was only 1 trisomic mouse from (Ts65Dn x B6C3.Dyrk1afl/fl) 
matings so no effect sizes are reported.   
a) Western Blots ran using Abnova Dyrk1a protein & normalizing to total protein load 
Age Group Cerebellum Hippocampus Cerebral Cortex 
P12 Eu (n=7) 1.00 ± 0.05 1.00 ± 0.07 1.00 ± 0.08 Ts (n=8) 1.19 ± 0.13 1.37 ± 0.14 1.15 ± 0.18 
Effect size d=0.62 d=0.82 d=0.44 
P15* Eu (n=6) 1.00 ± 0.11 1.00 ± 0.02 1.00 ± 0.07 Ts (n=7) 2.01 ± 0.27* 1.53 ± 0.07* 1.63 ± 0.16* 
Effect size d=1.90 d=3.99 d=1.90 
P18 Eu (n=7) 1.00 ± 0.06 1.00 ± 0.09 1.00 ± 0.05 Ts (n=7) 1.16 ± 0.13 1.29 ± 0.16 1.31 ± 0.17 
Effect size d=0.58 d=0.77 d=0.85 
P24 Eu (n=3) 1.00 ± 0.24 1.00 ± 0.32 1.00 ± 0.20 Ts (n=3) 1.11 ± 0.34 0.94 ± 0.20 0.76 ± 0.14 
Effect size d=0.19 d=0.05 d=1.43 
 
b) Western Blots ran using Bethyl Dyrk1a protein & normalizing to actin 
Age Group Cerebellum Hippocampus Cerebral Cortex 
P30 Eu (n=5) 1.00 ± 0.13 1.00 ± 0.10 1.00 ± 0.13 Ts (n=5) 1.08 ± 0.13 1.15 ± 0.10 0.76 ± 0.08 
Effect size d=0.54 d=0.97 d=1.01 
P42 Eu (n=3) 1.00 ± 0.04 1.00 ± 0.07 1.00 ± 0.24 Ts (n=1) 0.40  0.64  0.36  
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3.2.2 Dyrk1a protein levels at P15 
As shown in Figure 7, Ts65Dn male mice exhibited higher levels of Dyrk1a protein across 
all three brain regions versus euploid controls [mixed ANOVA, main effect of genotype: 
F(1,13)=35.83, p<0.001] at P15.  Follow up analyses showed Ts65Dn mice exhibited significantly 
higher levels of Dyrk1a protein versus euploid controls in the cerebellum [t(13)= -3.82, p=0.002, 
d=1.90], cerebral cortex [t(13)= -3.764, p=0.002, d=1.90], and hippocampus [t(13)= -7.025, 
p<0.001, d=3.99].  A Pearson’s correlation of Dyrk1a protein levels was run within each genotype 
in order to determine if Dyrk1a protein levels were significantly correlated across brain regions.  
There was a trend towards a significant correlation between Dyrk1a protein levels in the cerebral 
cortex and hippocampus in trisomic mice, suggesting a similar regulation mechanism for Dyrk1a 
in these two brain regions (r=0.751, p=0.052). 
Figure 7.  Dyrk1a protein levels in P15 male euploid and Ts65Dn mice from (Ts65Dn x 
B6C3.Dyrk1afl/fl) matings 
The Dyrk1a protein levels in the a) cerebellum, b) hippocampus and c) cerebral cortex of 
P15 male euploid and Ts65Dn mice.  Ts65Dn mice had significantly elevated levels versus 
euploid controls in each brain region, as indicated by the (*) (p<0.05).  Data are represented 
as mean ± SEM.  7d depicts a representative image of a western blot ran on two euploid 
(Eu) and two trisomic (Ts) male mice.  The values in yellow text below the green bands 
are the measure of Dyrk1a fluorescence.  The values in white text above the green bands 
represent the ratio of Dyrk1a fluorescence: total protein loaded, normalized to the euploids 
within each brain region.   Cerebellum (CB), Cerebral Cortex (CTX), Hippocampus (HP).  
After the fluorescent membrane in 7d was scanned, it was stained with coommasie dye, as 
seen in Figure 7e.  The total protein load was quantified by drawing identical rectangular 
boxes (outlined in yellow) in each lane.  The number above the lane represents the total 
amount of protein. 
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Figure 7 continued 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
3.2.3 Dyrk1a protein levels at P18 
A mixed ANOVA revealed no significant main or interactive effects of genotype in Dyrk1a 
protein at P18 in male Ts65Dn mice in the cerebral cortex [t(14)= -1.731, p=0.105, d=0.85], 
cerebellum [t(14)= -1.167, p=0.263, d=0.58], or the hippocampus [t(14)= -1.586, p=0.135, 
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d=0.77].  There was a strong trend for trisomic mice having elevated Dyrk1a protein levels across 
all brain regions (p=0.058) (see Table 4).   
3.2.4 Dyrk1a protein levels at P24 
As seen in Table 4a, there were no significant main or interactive effects of genotype on 
Dyrk1a protein levels  at P24 in male Ts65Dn mice in the cerebral cortex [t(4)= 1.753, p=0.154, 
d=1.43], cerebellum [t(4)= -0.221, p=0.836, d=0.19] or the hippocampus [t(4)= 0.064, p=0.952, 
d=0.05]. 
3.2.5 Dyrk1a protein levels at P30 
There were no significant main or interactive effects of genotype on Dyrk1a protein at P30 
in male Ts65Dn mice in the cerebral cortex [t(8)= 1.758, p=0.117, d=1.01], cerebellum [t(8)= -
0.895, p=0.397, d=0.54] or the hippocampus [t(8)= -1.584, p=0.152, d=0.97] (see Table 4b and 
Appendix).  
3.2.6 Dyrk1a protein levels at P42 
At P42, only 3 euploid and one trisomic mouse from (Ts65Dn x B6C3.Dyrk1afl/fl) matings 
underwent Western blot analysis to measure Dyrk1a protein levels.  No statistical analysis was run 
on these animals, and the averages and single blot levels are reported in Table 4b.  
3.3 Aim 2: Treatment with CX-4945 or DMSO from P14 – P18  
3.3.1 Attrition and treatment group sizes 
A total of 57 male mice were treated with either CX-4945 or 10% DMSO.  Three male 
mice died while receiving treatment.  Two euploid mice receiving CX-4945 treatment died on P18 
and one trisomic mouse receiving 10% DMSO was found dead on P18.  The primary statistical 
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analysis for SA2 includes only euploid and trisomic Dyrk1afl/+ mice; see the Appendix for 
additional analysis that include the mice from (Ts65Dn x B6C3F1) matings.  The final treatment 
group sizes and the number of litters represented from (Ts65Dn x B6C3.Dyrk1afl/fl) matings were 
as follows; Eu+DMSO (n=12, 5 litters), Eu+ CX+4945 (n=7, 4 litters), Ts+DMSO (n=9, 3 litters), 
Ts+CX-4945 (n=7, 3 litters). 
3.3.2. Body weight throughout treatment 
All male mice significantly increased their weight over the five days of treatment [main 
effect of day, F(4,124)=4.0, p=0.004].  However, trisomic mice had significantly lower body 
weights compared to euploid mice [main effect of genotype, F(1,31)=9.23, p=0.005] (Figure 8).   
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Figure 8.  Body weight trajectory across P14-P18 in offspring from (Ts65Dn x B6C3.Dyrk1afl/fl) 
matings 
All four treatment groups significantly increased their body weight over the course of five 
days of treatment, however, male trisomic mice had significantly smaller body weights 
compared to male euploids, as indicated by the (*).  Data are represented as mean ± SEM.    
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3.3.3 Locomotor activity 
There were no significant main or interactive effects of genotype or treatment on the total 
distance traveled in the locomotor task (Figure 9).   The current study also had an a priori 
hypothesis that trisomic mice treated with CX-4945 would exhibit significantly improved 
locomotion compared to trisomic mice treated with DMSO.  An independent samples t-test 
revealed no significant differences between these two groups [t(14)= 1.299, p=0.215, d=0.66].  
With the current group sizes of 7 (Ts+CX-4945) and 9 (Ts+DMSO), a post hoc power analysis 
demonstrated that the experiment only had a 22% power to detect differences between the current 
group means.  A power analysis was conducted (GraphPad StatMate) using effect sizes of the 
current experiment with power set at 0.50 and α=0.05, two-tailed.  In order for the Ts+CX-4945 
and Ts+DMSO group differences to reach significance, the sample sizes would have to increase 
to 18 mice per treatment group.  Therefore, the pattern of CX-4945 increasing trisomic locomotion 
activity could be due to an underpowered data set. 
A Pearson’s correlation was used to assess any relationship between body weight at the 
time of testing and total distance travelled.  Collapsed across all groups, there were no significant 
correlations between these two variables.  When run on each treatment group, only the Ts+DMSO 
group showed a significant positive correlation between body weight and total distance travelled 
(r=0.784, r2=0.614, n=9, p=0.012). 
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Figure 9.  The total distance travelled in a 10 minute locomotor activity test in offspring from 
(Ts65Dn x B6C3.Dyrk1afl/fl) matings 
There were no significant differences between the four treatment groups.  Data are 
represented as mean ± SEM. 
 
3.3.4 Homing task  
3.3.4.1 Total time spent exploring  
There were no significant main or interactive effects on the total time spent exploring both 
zones, although there was a strong trend towards euploid mice exhibiting significantly more 
exploration in trial 1 versus trisomic mice (p=0.058), as seen in Figure 10a.  An independent t-test 
was used to test the a priori hypothesis that trisomic mice treated with CX-4945 would exhibit 
significantly improved homing task behavior compared to trisomic mice treated with DMSO.  
There were no significant differences in the total time spent exploring both zones in trial 1 between 
Ts+DMSO and Ts+CX-4945 mice [t(13)=0.816, p=0.429, d=0.42].  The current study had a power 
of 12% to detect a differences between the group means.  A power analysis was conducted 
(GraphPad StatMate) using effect sizes of the current experiment with power set at 0.5 and α=0.05, 
two-tailed test.  The current group sizes would need to increase to approximately 24 animals per 
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group in order to significantly detect this difference.  There were no significant differences 
observed in trial 2.  When the total time spent exploring was summed across trials (trial 1 total 
time spent exploring + trial 2 total time spent exploring) euploid mice showed higher levels of 
exploration compared to trisomic mice [main effect of genotype, F(1,28)=4.2, p=0.048], as seen 
in Figure 10b. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 10.  Total time spent exploring both zones and sum exploration time in offspring from 
(Ts65Dn x B6C3.Dyrk1afl/fl) matings 
The total time spent exploring both zones across the four treatment groups during trial 1.  
In Figure 10a, there was a strong trend for euploid mice to spend more time exploring both 
the home cage and new cage bedding zone versus trisomic mice, although this did not reach 
significance (p=0.058).  Figure 10b represents the total time spent exploring summed 
across both trials (trial 1 total exploration time + trial 2 total exploration time).  When 
collapsed across trials, euploid mice spend significantly more time exploring than trisomic 
mice (as indicated by the *).  Data are represented as mean ± SEM. 
 
0
1 0
2 0
3 0
4 0
5 0
6 0
O ffs p r in g  F ro m  (T s 6 5 D n  x  B 6 C 3 .D y rk 1 a f l / f l) m a tin g s
 T r ia l 1 :  T o ta l T im e  S p e n t
E x p lo r in g  B o th  Z o n e s
Ti
m
e 
(S
ec
on
ds
)
E u  +  D M S O  (n = 1 1 )
E u  +  C X -4 9 4 5  (n = 6 )
T s  +  D M S O  (n = 8 )
T s +  C X -4 9 4 5  (n = 7 )
a)
0
2 0
4 0
6 0
8 0
1 0 0
1 2 0
 O ffs p r in g  F ro m  (T s 6 5 D n  x  B 6 C 3 .D y rk 1 a f l / f l) m a tin g s
S u m  E x p lo ra t io n  T im e
T
im
e
 (
S
e
c
o
n
d
s)
E u  +  D M S O  (n = 1 1 )
E u  +  C X -4 9 4 5  (n = 6 )
T s  +  D M S O  (n = 8 )
T s +  C X -4 9 4 5  (n = 7 )
*
b )
51 
 
3.3.4.2 Total midline crossings 
There were no significant differences between the groups on the number of midline 
crossings made in trial 1 or trial 2 (Table 5).  
3.3.4.3 Total time spent exploring home zone  
There was a trend for euploid mice to spend significantly more time in the home zone on 
trial 1 versus trisomic mice, however, this did not reach significance (p=0.08).  An independent t-
test was used to test the a priori hypothesis that trisomic mice treated with CX-4945 would exhibit 
significantly improved homing task behavior compared to trisomic mice treated with DMSO.  
There were no significant differences in the total time spent exploring the home zone in trial 1 
between Ts+DMSO and Ts+CX-4945 mice [t(13)= 1.128, p=0.280, d=0.57].  The current 
experiment had a power of 18% to detect a differences between the group means.   
A power analysis was conducted (GraphPad StatMate) using effect sizes of the current 
experiment with power set at 0.5 and α=0.05, two-tailed test.  The current group sizes would need 
to increase to approximately 15 animals per group in order to detect significant differences between 
Ts+DMSO and Ts+CX-4945 in the time spent exploring the home zone on trial 1.  There were no 
significant differences between euploid and trisomic mice in home zone exploration in trial 2.   
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Figure 11.  The total time spent exploring the home zone in trial 1 in offspring from (Ts65Dn x 
B6C3.Dyrk1afl/fl) matings 
There was a trend towards euploid mice spending more time exploring the zone containing 
the home cage bedding versus trisomic mice, but this did not reach significance (p=0.08).  
An independent t-test testing an a priori hypothesis between the two trisomic treatment 
groups did not reveal any significant differences, despite a moderate effect size (d=0.57).  
The power of the group sizes in the current study (18%) is no sufficient to detect the current 
mean group differences.  Data are represented as mean ± SEM. 
 
3.3.4.4 Number of home zone visits 
There were no significant main or interactive effects on the number of home zone visits in 
trial 1.  However, there was a significant treatment x genotype interaction on trial 2 [F(1,28)= 6.6, 
p=0.015], with Ts+DMSO mice visiting the home zone significantly more than the Euploid + 
DMSO treatment group, as seen in Figure 12. 
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Figure 12.  The total number of home visits on trial 2 in offspring from (Ts65Dn x 
B6C3.Dyrk1afl/fl) matings 
The Ts+DMSO group had significantly more home zone visits than the Eu+DMSO group, 
as indicated by the (*).  Data are represented as mean ± SEM.   
 
3.3.4.5 Total time spent exploring new zone 
There were no significant differences between groups on the total time spent exploring the 
new zone in trial 1.  However, euploid mice spent significantly more time exploring the new zone 
versus trisomic mice on trial 2 [main effect of genotype, F(1,28)=8.6, p=0.007], as seen in Figure 
13. 
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Figure 13.  The total time spent exploring the new zone in trial 2 in offspring from (Ts65Dn x 
B6C3.Dyrk1afl/fl) matings 
Data are represented as mean ± SEM.  Both euploid groups spent significantly more time 
exploring the new zone versus the trisomic treatment groups, as indicated by the (*). 
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3.3.4.6 Number of new zone visits 
There were no significant differences between groups in the number of new zone visits in 
trial 1 or trial 2 (Table 5).  
3.3.4.7 Time taken to first explore home zone and new zone 
There were no significant differences between groups on the time taken to first explore the 
home zone on trial 1 or trial 2.  In addition, there were no significant differences between groups 
on the time taken to first explore the new zone on trial 1 or trial 2 (Table 5). 
3.3.4.8 Home preference  
A home preference score was calculated as: [total time spent exploring home zone/ total 
time spent exploring home zone + total time spent exploring new zone].  There were no significant 
differences between groups on home preference scores on trial 1 or trial 2 (Table 5). 
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Table 5.  Non-significant homing task measures in offspring from (Ts65Dn x B6C3.Dyrk1afl/fl) 
matings 
There were no significant differences between genotypes or treatments in several homing 
measures from either trial 1 or trial 2.  Data are represented as mean ± SEM. 
 
 
 
3.3.5 Immunohistochemistry 
Euploid mice had significantly more BrdU-labeled cells counted throughout the dentate 
gyrus subventricular zone versus trisomic controls (Figure 14a) [main effect of genotype, 
F(1,23)=5.2, p=0.032].  Euploid mice also had a significantly larger dentate gyrus granule cell 
layer volume (Figure 14b) [F(1,23)=14.04, p=0.001]. However, CX-4945 treatment did not alter 
either of these effects.  
There were no significant main or interactive effects on the total number of slices counted 
or cellular density (Table 6).  Euploid mice treated with CX-4945 had significantly thicker slices 
[genotype x treatment interaction, F(1,23)=6.1, p=0.021].  This was likely due to random variation 
in vibratome slicing or differential shrinkage during the processing procedure.  LSD post hoc 
Trial Homing Measure
Eu+DMSO 
(n=11)
Eu+ CX-4945 
(n=6)
Ts+DMSO 
(n=8)
Ts+CX-4945 
(n=7)
Total midline crossings 2.36 ± 0.50 1.67 ± 0.84 2.38 ± 0.65 2.86 ± 0.88
Number of new zone visits 0.64 ± 0.24 1.17 ± 0.54 1.88 ± 0.44 0.86 ± 0.34
Time taken to first explore 
home zone 19.73 ± 4.3 17.67 ± 4.21 36.88 ± 6.48 21.71 ± 5.96
Time taken to first explore 
new zone 43.09 ± 6.8 36.50 ± 10.75 24.75 ± 9.46 32.29 ± 10.04
Home exploration 
preference 92.2 ± 3.1 80.45 ± 11.58 84.36 ± 8.31 76.77 ± 9.76
Total midline crossings 2.73 ± 0.71 3.67 ± 1.14 5.00 ± 0.90 3.43 ± 0.84
Number of new zone visits 2.55 ± 0.36 2.33 ± 0.84 1.75 ± 0.31 1.43 ± 0.36
Time taken to first explore 
home zone 30.00 ± 5.94 26.67 ± 10.44 12.63 ± 2.31 21.00 ± 7.30
Time taken to first explore 
new zone 9.45 ± 2.13 16.83 ± 8.77 17.50 ± 6.51 26.71 ± 9.07
Home exploration 
preference 51.48 ± 9.95 59.43 ± 11.49 70.15 ± 10.72 73.00 ± 12.66
Trial 1
Trial 2
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analysis showed that mice in the Eu+CX-4945 group had significantly thicker slices than the 
Eu+DMSO group (Table 6; p=0.021).  The average slice thickness for the Eu+CX-4945 group 
was 20.1µ versus 19.6µ for the Eu+DMSO group, see Table 6.  Group means for total volume of 
the dentate gyrus are also shown in Table 5. (Table 6).   
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Figure 14.  Total cell counts and granule cell layer volume in offspring from (Ts65Dn x 
B6C3.Dyrk1afl/fl) matings 
Figure 14a depicts the total estimated number of BrdU+ labeled cells throughout the DG.  
Euploid mice had a higher number of estimated total cells counted than trisomic mice, as 
indicated by the (*), p<0.05.  Figure 14b represents the estimated total DG granule cell 
layer volume, euploid mice had a significantly greater volume than trisomic mice, as 
indicated by the (*).  Data are represented as mean ± SEM. 
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Table 6.  Anatomical DG measures in offspring from (Ts65Dn x B6C3.Dyrk1afl/fl) matings 
There were no differences between Euploid (Eu) and Trisomic (Ts) groups in the total 
number of slices examined or cell density.  There was a significant difference in total cell 
counts, with Eu mice have higher cell counts than Ts mice, as well as in total dentate gyrus 
volume, with Eu mice displaying a significantly greater volume than trisomic mice. 
Group Slices Thickness 
Total 
Cell 
Coun
ts (Q-) 
 
Estimated Total 
Cell Counts of 
DG 
[(Q-)/(# of 
slices)] * 5 
 
 
 
Estimated 
Total Volume 
of DG (mm3) 
Cell Density 
(cells/mm3) 
 
Eu+DMSO 
(n=9) 
11 ± 
0.37 
19.6 ± 
0.1 
663.2 
± 90  306.3 ± 41.3  
 
3.308 ± 
0.15x108 
10.0x10-6 ± 
1.26x10-6 
 
Eu+CX-
4945 (n=5) 
11.2 ± 
0.4 
20.1 ± 
0.1 
650.0 
± 136  285.1 ± 58.0  
 
3.56x108 ± 
0.08x108 
9.1x10-6 ± 
1.90x10-6 
 
Ts+DMSO 
(n=6) 
10.8 ± 
0.3 
19.9 ± 
0.1 
479 ± 
60  222.1±27.6  
 
2.7x108 ± 
0.14x108 
8.6x10-6 ± 
0.99x10-6 
 
Ts+CX-4945 
(n=7) 
11.6 ± 
0.2 
19.5 ± 
0.1 
424 ± 
42  184.6±20.1  
 
2.9x108 ± 
0.11x108 
7.0x10-6 ± 
0.64x10-6 
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CHAPTER 4. DISCUSSION  
4.1 Two significant considerations for data interpretation 
There are two important findings that emerged from the current study that should be 
addressed.  First, the background of trisomic mice should be carefully monitored.  In the current 
study, trisomic mice from two slightly different backgrounds were used for two main reasons.  The 
laboratory was currently generating Ts65Dn mice that carried a floxed allele of Dyrk1a for use in 
a future study (Ts65Dn.Dyrk1afl/+).  These mice had very similar backgrounds to the traditional 
Ts65Dn mice that have been extensively used in our laboratory (Stringer et al., 2015; Stringer et 
al., 2017).  Presumably, the only significant difference between Ts65Dn.Dyrk1afl/+ and Ts65Dn 
mice was the presence of a single floxed Dyrk1a allele.  This floxed allele was not functionally 
active and it was assumed that the utilization of both breeding schemes would yield identical 
outcomes.  A second reason for utilizing these mice is that Ts65Dn are difficult to breed (Roper et 
al., 2006) and it was hypothesized that the use of Ts65Dn.Dyrk1afl/+ mice would allow for an 
adequate production of mice.  However, it became obvious near the end of SA2 that there were 
differences between the two breeding schemes.   
As mentioned in the results, there was not enough statistical power to draw significant 
conclusions about any differences between the two different breeding schemes of mice.  It was 
observed that (Ts65Dn x B6C3.Dyrk1afl/fl) F6-F8 matings generally resulted in larger litter sizes.  
However, there were no significant differences between the two breeding schemes in the size of 
the litters or the percent of trisomic mice produced within a litter.  Both breeding schemes averaged 
~50% trisomic mouse production within a given litter, which is higher than previously reported 
(Roper et al., 2006).  The current study only analzyed 6 (Ts65Dn x B6C3F1) and 11 (Ts65Dn x 
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B6C3.Dyrk1afl/fl) litters, so additional litters will need to be assessed in order to determine if there 
are any significant differences in litter demographics (litter size, % of trisomic mice within a litter).  
The offspring from the (Ts65Dn x B6C3.Dyrk1afl/fl) F6-F8 matings also appeared to weigh 
significantly more than those from the (Ts65Dn x B6C3F1) matings, especially between 
Ts65Dn.Dyrk1afl/+ and Ts65Dn mice.  There are a few factors that could be contributing to these 
apparent differences.  First, there could be specific genes that are fixed in the 
Ts65Dn.Dyrk1afl/+and euploid.Dyrk1afl/+ mice.  The B6C3.Dyrk1afl/fl mice were used for mating 
after ~7-9 generations of inbreeding.  At this stage, approximately ~70% of the genome is fixed 
and one piece of evidence supporting this is that B6C3.Dyrk1afl/fl mice all had a black coat color 
whereas B6C3F1 mice have an agouti coat color (Silver, 1995).  One possibility is that a gene 
involved in development or vitality could also be fixed, resulting in the trend towards significantly 
heavier mice.  This could suggest that offspring from (Ts65Dn x B6C3F1.Dyrk1afl/fl) matings 
exhibit significantly higher hybrid vigor compared to offspring from (Ts65Dn x B6C3F1) matings.  
One of the main differences between the Ts65Dn.Dyrk1afl/+ and Ts65Dn mice is the presence of a 
floxed Dyrk1a allele.  It is possible that the floxed allele could be “leaky”, altering Dyrk1a 
expression even without Cre-recombinase.  However, Ts65Dn.Dyrk1afl/+ mice exhibited 
significantly elevated Dyrk1a protein levels versus euploid.Dyrk1afl/+ mice, so this possibility is 
unlikely.  Nevertheless, future studies should monitor the genetic background of trisomic mice in 
order to ensure consistencies within a laboratory and across the DS research field. 
There was a lack of significant behavioral improvements after CX-4945 treatment from 
P14-P18.  However, this could be due to the lack of power observed in the current study.  After 
differences between the two breeding schemes of mice were observed, it was determined to solely 
analyze and report results on offspring from the (Ts65Dn x B6C3.Dyrk1afl/fl) matings.  This was 
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the most appropriate approach as the elevation of Dyrk1a protein at P15 (which was the basis for 
the timing of the CX-4945 treatment) was composed solely of male mice from the (Ts65Dn x 
B6C3F1.Dyrk1afl/fl) matings.  A consequence of this decision was a reduction in sample sizes, 
especially in both of the trisomic treatment groups.  When analyzing the locomotor activity and 
homing test measures, there was no reported significant effects, but there appeared to be a pattern 
of improved phenotypes in trisomic mice treated with CX-4945.  To probe this pattern further, the 
effect sizes were calculated and many of the behavioral outcomes that lack statistical significance 
showed modest effect sizes, ranging from 0.42 – 0.67.  A subsequent power analysis on this data 
showed that the majority of the outcomes measured in the current study were significantly 
underpowered to detect the observable group differences.  This was also seen in SA1, as there 
were strong trends towards trisomic mice exhibiting significantly elevated Dyrk1a protein levels 
across all three brain regions at P12 and P18.  The following discussion section takes these findings 
into consideration while discussing the implications of the outcomes of the current study. 
4.2 Peak elevations of Dyrk1a protein levels occur at P15 in Ts65Dn mice  
This study was the first to systematically assess perinatal and adolescent levels of Dyrk1a 
protein in the cerebellum, cerebral cortex and hippocampus of Ts65Dn male mice.  Ts65Dn mice 
displayed significant elevated levels of Dyrk1a protein with a large effect size at P15 in the 
cerebellum, cerebral cortex and hippocampus, with non-significant trends towards elevation on 
P12(p=0.08) and P18 (p=0.058).  These non-significant trends showed strong effect sizes (see 
Table 4), which could mean that Dyrk1a is in fact elevated in trisomic mice at these ages, however, 
the current study was underpowered and was unable to detect a significant elevation.  Though 
Dyrk1a tended to be higher in trisomic mice compared to euploid controls, the effects were largest 
at P15 and never reached significance at the other ages (P24, P30, P42).   
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Currently, there is only one other study that has examined Dyrk1a protein levels in the 
Ts65Dn mouse between E11.5 and 6 weeks of age.  Yin et al. examined Dyrk1a protein levels in 
the forebrain at P5, P10, P15, P20, P25, P30 and P35 in Ts65Dn mice (sex not specified) (Yin et 
al., 2017).  They reported that trisomic mice had significantly elevated levels of Dyrk1a protein at 
all seven ages.  However, there are several differences between the current study and Yin et al. 
(Yin et al., 2017).  
First, the current study assessed Dyrk1a protein levels in the cerebellum, cerebral cortex 
and hippocampus, whereas the Yin et al. examined Dyrk1a protein levels in the forebrain 
(unknown whether the entire forebrain was extracted).  Differences in Dyrk1a protein levels 
between these brain regions is not surprising, considering the growing evidence that the regulation 
and expression of Dyrk1a protein is likely temporally and spatially tissue specific.  The current 
study also utilized a different quantification method for Dyrk1a protein, using total protein staining 
as a loading control.  In contrast, Yin et al. used the traditionally used housekeeping protein actin 
as a loading control.  Recent evidence suggests that total protein may be a superior control, as β-
actin levels can be affected by neurological diseases and alterations in cellular processes (Eaton et 
al., 2013; Aldridge et al., 2008).  Alterations in β-actin levels in Ts65Dn mice have not been 
published, but differences in β-actin levels across brain regions has been observed in our 
laboratory.  Yin et al. did not report on any differences in β-actin levels, but their small group sizes 
(3-5) may be insignificant to detect differences.  Interestingly, they did report that Dyrk1a protein 
levels did decrease with age in both the euploid and trisomic mice, but it is unknown whether β-
actin levels changed as well.  In addition, it is unknown if males and/or females were used for 
Western blot analysis, as sexual dimorphisms may impact Dyrk1a protein levels (Yin et al., 2017).  
Stringer et al. (2017) reported that P42 Ts65Dn mice exhibited significantly lower levels of Dyrk1a 
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in the cerebellum versus euploid controls, but found no differences in Dyrk1a protein levels in the 
cerebral cortex or hippocampus.  In contrast, the majority of studies examining adult Ts65Dn mice 
(>3.5 months of age) have reported significant elevations in Dyrk1a protein levels (Stringer et al., 
2017).  However, many of these studies either examined the entire brain (brain homogenate) or 
examined a single brain region.  It is crucial that future studies try and determine Dyrk1a protein 
levels across multiple brain regions, as this will be a necessary step towards understanding the 
expression landscape of Dyrk1a in Ts65Dn mice.    
4.2 What is known about Dyrk1a expression and its connection to brain deficits? 
Dyrk1a expression studies conducted in normally developing mice could help hypothesize 
which tissues to target and analyze for expression in Ts65Dn mice.  Dyrk1a expression is observed 
at E8 in the telencephalon and prospective spinal cord, then gradually migrates caudo-laterally 
(E8.5-9.5) and dorso-medially (E10). This direction of expression follows the typical neurogenesis 
path, supporting its role in this process (Hämmerle et al., 2008).  Dyrk1a was observed outside of 
these developing nervous tissues, such as in migrating neural crest cells and the branchial arch.  
E11, E17 and adult mice displayed Mnb/Dyrk1a expression in the olfactory bulb, cerebellum, 
cortex, piriform cortex, hippocampus, hypothalamus, spinal cord and retina (Guimerâ et al., 1996; 
Song et al., 1996; Rahmani et al., 1998).  This pattern of expression in multiple CNS regions 
parallels the influential role of Dyrk1a in several developmental processes (Duchon et al., 2016). 
At the protein level, Dyrk1a is expressed at several embryonic stages (E14.5, E16.5) 
throughout the cortical layers, including co-localizing with TUJ1 (Neuron-specific Class III β-
tubulin) and NeuN (neuronal specific nuclear protein) in forebrain neurons, and is observed in the 
nucleus of cells from the ventricular zone in ICR mice (Hämmerle et al., 2008).  At P5, Dyrk1a is 
localized in the Purkinje cell nucleus in cerebellar cells, and a high co-localization with MAP2 and 
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Dynamin 1 (microtubule-associated proteins) at P8 was observed (Hämmerle et al., 2008).   At 
P14, significant Dyrk1a expression was detected in the external granular, molecular layer and 
internal granule cell layer of the cerebral cortex (mouse model unknown) (Martı́ et al., 2003).  In 
adult ICR mice, Dyrk1a protein was localized in the soma and dendrites, as well as the nucleus of 
cerebral cortex pyramidal neurons (Hämmerle et al., 2008).  A fractionation-based Western blot 
on frontal cortex tissue extracted from adult and aged Ts65Dn mice revealed that Dyrk1a was 
primarily located in the cytoskeleton.  This cytoskeleton fraction also contained synaptic proteins 
(synapsin 1), suggesting that Dyrk1a could primarily localized in cytoskeleton within a synapse.  
Dyrk1a was also observed in the nucleus and cytosol (Kaczmarski et al., 2014).  In contrast, 
Dyrk1a was primarily localized within the nucleus of DG granule cells of adult ICR mice 
(Hämmerle et al., 2008).  The high level of Dyrk1a expression throughout these brain regions 
suggest that its overexpression influences phenotypes associated with those regions.  
 In the current study, strong trends for trisomic mice exhibiting elevated Dyrk1a protein 
levels at P12 (p=0.08) and P18 (p=0.058) were observed, suggesting that Dyrk1a is highly 
expressed during Ts65Dn perinatal development.  Dyrk1a expression studies have not been 
extensively conducted in Ts65Dn mice, but Ts65Dn mice do exhibit deficient phenotypes in these 
brain regions during neonatal and perinatal ages.  For example, Ts65Dn mice exhibit deficits in 
embryonic corticogenesis such as decreases in neocortical layer thickness, reductions in cellular 
density, and a slower cell cycle in neocortical progenitors (Chakrabarti et al., 2007).  At postnatal 
ages, P22 Ts65Dn mice exhibit dendritic and synaptic abnormalities in the hippocampus 
(Belichenko et al., 2004).  Ts65Dn mice exhibit deficits in perinatal hippocampal neurogenesis 
including a reduction in BrdU-labeled DG cell proliferation, cell survival, the number of DG 
granule cells and the number of neural precursors (Bianchi et al., 2010; Stagni et al., 2016).  
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Decreased cell proliferation is also seen in fetuses (~17-20 week) with DS (Contestabile et al., 
2007).  In the cerebellum, Ts65Dn mice exhibit numerous structural deficits including a smaller 
cerebellar volume and a reduction in granule cell number (Baxter et al., 2000; Roper et al., 2006).   
At P14, Ts65Dn mice exhibit a significant reduction in internal granular layer (IGL) thickness, 
which could be attributed to the reduction in granule cell precursor (GCP) mitosis observed 
beginning at P0 (Roper et al., 2006).  Many of these histological deficits are thought to be the cause 
of cell cycle dysfunction, to which Dyrk1a overexpression has been strongly linked.  For example, 
an overexpression of Dyrk1a (observed in the current study) is hypothesized to cause cell cycle 
dysregulation in mouse models of DS (Haydar et al., 2012).  Of particular interest is the G1/S 
phase, a crucial time when cells will either leave the cell cycle in order to differentiate, or pass 
through the G1 checkpoint and commit to entering the cell cycle to undergo another round of cell 
division (Ohnuma et al., 2003). Studies using neural cell lines have demonstrated that expression 
of MNB/DYRK1A or Dyrk1a induces neuronal differentiation (Yang et al., 2001; Kelly et al., 
2005); however, its stable overexpression appears to impair normal neuronal differentiation (Park 
et al., 2007). Thus, the transient expression of Dyrk1a could promote cell cycle exit, and its 
subsequent down regulation allows cells to undergo neuronal differentiation (Hämmerle et al., 
2008; Tejedor and Hämmerle, 2011). This mechanism of action could be attributed to the ability 
of Dyrk1a to phosphorylate and possibly regulate two major cell cycle proteins; Cyclin D1 and 
p27 (Najas et al., 2015; Tejedor and Hämmerle, 2011). Cyclin D1 promotes G1-to-S phase 
transition and is required for cell proliferation. The protein p27 is crucial for neuronal 
differentiation, and promotes cell cycle exit (Hindley et al., 2012; Frank et al., 2009).  The 
regulation of these two key cell cycle components is necessary for an appropriate “speed” at which 
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the cell cycle phases occur, resulting in a balance between the number of progenitor cells and the 
production of differentiated neurons (Salomoni et al., 2010). 
Overexpression of DYRK1A/Dyrk1a both in vivo and in vitro results in the nuclear export 
of Cyclin D1, resulting in reductions in Cyclin D1 protein levels at multiple developmental ages 
in TgDyrk1a mice (E11.5 & E14.5) (Yabut et al., 2010; Park et al., 2010; Soppa et al., 2014; Najas 
et al., 2015).  In addition, DYRK1A/Dyrk1a overexpression results in more cells in the G1/0 phase 
versus S or G2/M phase, resulting in a cell proliferation deficits, premature cell exit and 
differentiation, and the nuclear export of Cyclin D1 (Soppa et al., 2014; Najas et al., 2015).  In 
Ts65Dn, E11.5, embryos contain 1.5 fold more Dyrk1a protein, and display significant decreases 
in Cyclin D1 levels.  Normalization of Dyrk1a copy number restored levels of Cyclin D1, the 
number of intermediate progenitors, as well as the production of neurons at multiple 
developmental time points (Najas et al., 2015). 
Although the deficits in cortical, hippocampal and cerebellar formation in Ts65Dn mice 
are well established, a connection between these deficits and an observable behavioral phenotype 
at a specific age is not well understood.  The current study discovered that Dyrk1a protein is 
significantly elevated at P15, which could be directly affecting the observed hippocampal 
neurogenesis deficit via hyperphoshporylation of cell cycle proteins (i.e. Cyclin D1).  However, 
future studies will need to determine in what cell types (i.e. pyramidal cells, neurons, Purkinje 
cells) and where Dyrk1a localizes (nucleus, cytosol) in order to pursue hypotheses concerning 
which specific substrates and intracellular processes Dyrk1a could be regulating.  Dyrk1a 
phosphorylation regulates substrates located in both the nucleus and cytosol, and this regulation is 
likely to be tissue and time-specific (Martı́ et al., 2003; Kaczmarski et al., 2014; de Graaf et al., 
2004; Woods et al., 2001; Arron et al., 2006; Chen-Hwang et al., 2002).  While Dyrk1a may be 
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mediating proliferation deficits through Cyclin D1 phosphorylation during embryonic ages, this 
has not yet been established for perinatal Ts65Dn mice.  Assessing protein levels in a brain region 
is a fundamental first step towards understanding the influence of Dyrk1a on phenotypes. To 
strengthen the current study’s findings, research should look to analyze Dyrk1a expression on a 
cellular level in order to develop a comprehensive understanding of Dyrk1a expression in a specific 
brain region at a specific age.    
4.3 Behavioral and histological phenotypes in perinatal euploid and Ts65Dn mice 
4.3.1 Locomotor activity 
There were no significant differences in locomotor activity between euploid and trisomic 
mice, although trisomic mice did exhibit a non-significant trend towards hypoactive behavior.  In 
addition, the administration of CX-4945 alter locomotion in any of the treatment groups.  As 
previously mentioned, there was a moderate effect size observed (d=0.66) despite the non-
significant p value.  A power analysis revealed that the current sample sizes were too low to detect 
the group differences of the effect size indicated by the current data.  The group sizes would need 
to increase to 11 mice per group in order to detect these differences.  Therefore, while the 
improvements in locomotion in mice treated with CX-4945 did not reach statistical significance, 
the moderate effect sizes and low group numbers warrant a further investigation of the effects of 
CX-4945 on locomotion.  
Trisomic mice who weighed below 5.4 grams at the time of locomotor testing had severe 
deficits in locomotor activity, as many exhibited a complete lack of movement during the trial.  
Trisomic mice who weighed over 5.4 grams still exhibited hypo-locomotion as compared to 
euploid mice.  Thus, weighing under 5.4 grams could be below a threshold stage of developmental 
maturation needed for to attain ambulatory activity typical for normally developing euploid mice 
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in this specific task.  With weight significantly influencing locomotor performance in the trisomic 
mice, this raises the possibility that the age at which the mice were tested or the type of task used 
here may not be appropriate to evaluate locomotor activity in perinatal Ts65Dn mice.    For 
example, Ts65Dn exhibit hyperactive behavior at P21 but the mice tested in the current study were 
younger (P16 or P17).  The developmental delays in the younger Ts65Dn mice may be more 
pronounced than at P21, which could explain the deficits in locomotion that were observed.   The 
apparatus used to measure locomotor activity at P21 in Ts65Dn mice was smaller than the chamber 
used here, and there was a “stimulus” object placed in the center of the apparatus (Holtzman et al., 
1996).  The smaller apparatus, combined with an object in the activity space might be a more 
motivating environment for the trisomic mice to explore.  The lack of trisomic locomotion in the 
current study appears to be task-dependent, as there were no differences between the euploid and 
trisomic groups in the number of midline crossings in the homing task.  In addition, the 
experimenter observed smaller mice that were placed in the chamber to move towards a corner 
and remain stationary throughout the task.  Future studies should take into careful consideration 
the developmental maturity (correlated with weight) of the animals being tested, and adjust the 
activity chamber settings as needed. 
This perinatal phenotype is especially interesting considering that at older ages, while 
trisomic mice still weigh less than euploid controls (Roper et al., 2006), they generally display a 
hyperactive phenotype (Stringer et al., 2015; Reeves et al., 1995)  However, this phenotype is 
variable depending on the age at which mice were tested (Martı́nez-Cué et al., 2002), whether an 
open field task or 24-hour home cage locomotion was utilized (Rueda et al., 2008; Stewart et al., 
2007), as well as the length and lighting conditions of the task (Coussons-Read et al., 1996; 
Escorihuela et al., 1995; Llorens-Martin et al., 2010; Sago et al., 2000).  These varying outcomes 
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highlight the method-dependent variability of activity phenotypes observed in Ts65Dn mice, and 
suggest that factors, such as the age of the mice and the length of the activity test, should be taken 
into consideration by future studies.  Linking locomotor defects to a specific gene, such as Dyrk1a, 
has been difficult for the DS research field.   Transgenic mice overexpressing Dyrk1a have also 
yielded contrasting findings for hyperactive behavior (Branchi et al., 2004; Ortiz-Abalia et al., 
2008).  When Dyrk1a  is normalized via the delivery of a short hairpin RNA (shRNA) to the 
striatum, hyperactive behavior was normalized in 2-3 month old TgDyrk1a mice (Ortiz-Abalia et 
al., 2008).  However, when Dyrk1a expression was normalized from conception, Ts65Dn mice 
still exhibited a hyperactive phenotype in the open field task at approximately 5-6 months of age 
(García-Cerro et al., 2014).  Thus, there are likely multiple genetic influences on the activity 
phenotype that are both spatially and temporally dependent.   
4.3.2 Homing task 
The modified homing task used here showed that euploid mice spent more time exploring 
both zones across the two trials, indicative of an exploration deficit in trisomic mice.  In addition, 
euploid mice spent significantly more time exploring the new zone on trial 2.  There were no 
significant differences in the number of midline crossings, suggesting that the exploration deficit 
observed in trisomic mice was not due to motor deficits.  Similar to the locomotor task, the 
administration of CX-4945 did not significantly alter any of the homing task measures in either 
the euploid or trisomic groups.  Although the outcomes did not reach statistical significance, 
moderate effect sizes were still observed (0.42-0.57) and many of the homing measures were 
underpowered, (1-β = 0.12-0.18) limiting the ability to detect the observable group differences. 
Additional mice in each treatment group will need to be added in order to more conclusively state 
the effect of CX-4945 on homing task behavior. 
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The homing task as used in this study may be best considered an assessment of pre-weaning 
exploratory behavior, in addition to utilizing olfaction, as eye opening had already occurred in all 
mice at the time of testing.  The utilization of a second trial in the current homing task methodology 
was to determine if mice had a persistent preference for the zone containing the home cage 
bedding, regardless of which zone (zone 1 or zone 2) it was located in.  The switching of the stimuli 
location from trial 1 to trial 2 controlled for any spatial preference that may have been present from 
trial 1.  The starting location of the two types of bedding was counterbalanced across animals, 
however it is difficult to ensure balanced starting locations of each bedding when also blind to 
genotypes.  Thus, future studies should take this into consideration in order to optimize this task 
and reduce any unnecessary biases.   
To date, there are only a few studies assessing homing behavior in Ts65Dn and other mouse 
models of DS.  These studies all used the same homing task methodology by placing home cage 
bedding across 1/3 of a new, empty cage.  The mice were placed up against the wall (opposite the 
home cage bedding) and the time to enter the home cage bedding was recorded.  Ts65Dn mice are 
significantly slower to reach home cage bedding than euploid controls at P12 (Holtzman et al., 
1996), with similar deficits reported at P14 in a transgenic Dyrk1a mouse model (Altafaj et al., 
2001) and at P12 in the Ts1Cje mouse model of DS (Guedj et al., 2015).  In these studies, olfaction 
significantly contributed to performance, as the homing task was administered before eye opening.  
Dyrk1a expression in the olfactory bulb in young mouse models of DS is not known, but it is 
highly expressed in adult mice (strain unknown).  If this patterning is similar in young mouse 
models of DS, conducting the homing task so that it relies on olfaction may be a step towards 
linking Dyrk1a to an olfactory-based homing task deficit.     
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4.3.3 Cell proliferation 
This study found that at P18, euploid mice had significantly more BrdU-labeled cells and 
a greater DG granule cell layer volume compared to trisomic mice.  However, CX-4945 did not 
significantly alter the number of BrdU+ cells in either group, indicating it did not change 
proliferation of neuroprogenitor cells in the DG.  In addition, there were no significant differences 
between groups in the number of slices counted or cell density.  However, the current study only 
had 11% power to detect the current group differences.  In accordance with a a priori hypothesis, 
an independent t-test between Eu+DMSO and Ts+DMSO groups on cell density revealed no 
significant differences, but a moderate effect size [t(13)= 0.768, p=0.456, d=0.41]. Consistent with 
our findings, 18-day-old Ts65Dn mice are reported to have deficits in proliferating BrdU+ labeled 
cells in the DG, although this study did not report any cell density or volume measures 
(Contestabile et al., 2007).  Another study examined Ts65Dn mice at P15 and found that trisomic 
mice exhibited reduced proliferation as indicated by a reduced number of BrdU+ cells in the DG, 
as well as reduced granule cell layer volume and granule cell density (Bianchi et al., 2010).  That 
study agrees with our finding of a cell proliferation DG granule cell layer volume deficit at P18, 
however, differences in granule cell density did not reach significance in our study..  When 
comparing across these three studies, the methods were very similar, with mice given a BrdU 
injection (100-150mg/kg) and sacrificed 2 hours later.  The other two studies did have fewer 
animals per group (3-6 versus 7-9 for the current study) but the high methodological similarities 
between these three studies confirms a strong cell proliferation deficit in Ts65Dn mice between 
P15 and P18.  A deficit in cell proliferation could lead to a significant decrease in the number of 
new neurons in the DG, which has been strongly linked to learning in animal models (Leuner et 
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al., 2006).  Thus, the proliferation deficit observed in Ts65Dn mice could significantly contribute 
to the learning and memory deficits that are also observed in these mice. 
4.4 What are the best behavioral tasks to use in perinatal euploid and Ts65Dn mice? 
With a push for therapeutics to occur earlier in Ts65Dn development, it is important to 
establish a consistent battery of behavioral and developmental assessments to determine the safety 
and efficacy of potential therapeutics (Guedj et al., 2014; Stagni et al., 2015).  Neonatal and 
perinatal developmental milestones are typically observed  P0 and P18, and ideally are measured 
over multiple days (Hill et al., 2008; Fox, 1965).  The ability of the homing task to be modified to 
assess general locomotor activity and exploratory behavior in a single trial/day is a powerful tool 
for assessing perinatal behavior.  Since there are few developmental milestones that have not been 
reached by P18, the homing task could serve as a useful assessment during that specific 
developmental period.  The locomotor test used here may not be sensitive to detect locomotor 
deficits in Ts65Dn mice.  Ts65Dn mice exhibit hyperactive behavior starting at P21, but it is 
possible that at earlier ages the mice are hypoactive due to developmental delay.  If this is true, the 
testing conditions used here (large chambers; 10-minute sessions; room temperature) may have 
suppressed activity in the Ts65Dn mice, considering that their significantly lower body weight 
likely correlates with general developmental delay relative to euploid controls. Alternate 
locomotor testing (i.e. smaller box, shorter test, warmer environment) may help determine if this 
hypoactive phenotype is persistent across different behavioral paradigms.   Reduced DG cell 
proliferation and granule cell neurogenesis is a consistently reported phenotype in perinatal 
Ts65Dn mice.  Linking this cellular deficit to a specific cognitive or behavioral phenotype is a 
challenge.  Many studies that administer perinatal treatments in DS mouse models either look at 
histological phenotypes immediately after the cessation of treatment, such as cell proliferation in 
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the DG, or the mice are allowed to age and phenotypes during adolescence and early adulthood 
are assessed (Bianchi et al., 2010; Stagni et al., 2016; Roper et al., 2006; Stagni et al., 2013).  One 
example of this was the administration of 50mg/kg/day [0.4mg/mL] of EGCG to Ts65Dn mice 
starting at P22-P97 (Stringer, unpublished results).  Starting on P75, the mice were trained on a 
pattern separation radial arm maze, which is thought to rely on the function of newly generated 
granule cells in the DG.  The mice received treatment throughout the testing, and cell proliferation 
in the DG was assessed on P97.  While EGCG treatment did not significantly improve Ts65Dn 
performance on the task or DG cell proliferation, the study adds to the growing number of studies 
administering therapeutics to perinatal/young adolescent Ts65Dn mice.  As previously mentioned, 
the behavioral phenotypes of Ts65Dn mice from P14- weaning are not as well established as 
neonatal or adolescent/adult phenotypes.  If perinatal age is a therapeutic target, additional studies 
will be needed to establish the trajectory of various cognitive and behavioral phenotypes during 
this time. 
Many of the behavioral outcomes reported here were underpowered, despite moderate 
effect sizes.  It will be important for future studies to use fully-powered designs and select 
behavioral tasks and measurable outcomes that are sensitive to CX-4945 treatment.  For example, 
the current utilization of the locomotor chambers may be too aversive of an environment to detect 
differences in perinatal euploid and trisomic mice.  Despite this, there was still strong effect sizes 
observed between Ts+DMSO and Ts+CX-4945 groups.  If adequate numbers of subjects were 
included or a more sensitive locomotion task was used (smaller apparatus, stimulus object), the 
effect of CX-4945 on this behavior may be more conclusive.   
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4.5 Lack of phenotypic improvements with 75mg/kg CX-4945 from P14-P18 in Ts65Dn 
mice 
A single injection of 75mg/kg/day of CX-4945 was used in the current study and there was 
a lack of statistically significant improvements across multiple phenotypes.  It is reiterated, 
however, that moderate effect sizes were observed and a pattern of improved locomotor behavior 
and homing task performance was observed in the Ts+CX-4945 treatment group.  In addition to 
evaluating the potential effect of CX-4945 treatment parameters on the reported outcomes, the 
possibility of underpowered group sizes could also be driving the lack of phenotypic improvement.  
The current study’s dose of 75mg/kg/day was largely based on a recent study that 
administered 75mg/kg to transgenic Dyrk1a mice via oral gavage (Kim et al., 2016).  That study 
reported that 30 minutes after a single dose of CX-4945, transgenic Dyrk1a mice had a significant 
reduction in phosphorylated tau levels in the hippocampus versus transgenic Dyrk1a mice given 
DMSO (Kim et al., 2016).  With this evidence, 75mg/kg a day was chosen as a starting dose for 
perinatal Ts65Dn mice.  While the previously mentioned study used oral gavage, this would be 
difficult to administer and stressful to pre-weaning animals, so it was decided that a SC injection 
would be a less aversive option for route of administration.  The significant effects observed with 
75mg/kg in adult mice suggested that this dose would be sufficient to observe significant 
improvements in perinatal mouse phenotypes.  Studies using CX-4945 commonly administered 
CX-4945 twice a day, however, disturbing the pre-weaning animals twice a day could be a 
significant stressor.  One possibility is that the current dose of CX-4945 is too high.  No adverse 
phenotypes were observed in euploid mice (2 copies of Dyrk1a) receiving CX-4945.  If CX-4945 
was inhibiting Dyrk1a below a normal threshold level, we might see negative outcomes in the 
euploid mice.   
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Another possibility is that 75mg/kg a day is not a high enough dose.  Studies have used 
significantly higher doses in mouse models of cancer, but there are several factors to consider.  
First, different routes of administration (ROA) of the same CX-4945 dose could produce different 
outcomes.  The breakdown and metabolism of CX-4945 is not known and depending on the solvent 
used to mix CX-4945 (current study used DMSO), there may be variations in its pharmacokinetic 
properties.  It will be important for future studies to assess if there is an optimal ROA for CX-4945 
treatment.  In addition, DMSO was used to suspend CX-4945 in solution (25mM CX-4945 
dissolved with 90% PBS and 10% DMSO).  This equated to a 10g mouse receiving ~10µL of 
DMSO, or ~1µl/g dose of DMSO.  DMSO is commonly used as solvent for water-insoluble 
compounds (Santos et al., 2003; Broadwell et al., 1982).  However, adverse side effects after in 
vivo administration of DMSO have been reported.  For example, Swiss albino mice (~20-30 grams) 
given an IP injection of DMSO solutions greater than 25% exhibited significantly altered mortality 
rates (Worthley et al., 1969).  An IP injection of 1µL/g or 0.5µL/g [90% Saline & 10% DMSO or 
95% saline & 5% DMSO] to 6-8 week old CD-1 mice did not alter rotarod performance.  However, 
adverse side effects have been reported at 1µL/g and lower doses.  Eight hours after a single 
0.3µL/g dose in P7 mice, there was a significant increase in the rate of apoptosis throughout the 
cerebrum (Hanslick et al., 2009).  This dose of DMSO is approximately half of what the mice in 
the current study received.   The study also reported significant increases in apoptosis in P7 mice 
after single doses of 1.25, 3 and 10µL/g.  In addition to P7 mice, P17 mice were also treated with 
a single 10µL/g DMSO injection, where significant white matter degeneration and high levels of 
cell apoptosis in the DG were observed.  There were no other doses examined in the P17 animals, 
and while a 10µL/g injection DMSO is significantly more than the current study administered, the 
adverse apoptotic findings at P7 with 0.3µL/g DMSO suggest that there could be adverse cellular 
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effects with the administration of 1µL/g DMSO (Hanslick et al., 2009).  Differences in 
neurogenesis between animals receiving a daily saline or DMSO IP injection (0.3µL/g) from P16-
P28 have been reported, although these  two groups were not statistically compared (George et al., 
2013).   
If the current study doubled the dose (maintaining a 25mM concentration) to 150mg/kg, a 
10g mouse would receive ~17 µL of DMSO.  Not only would this be a significant volume amount 
to inject (~170µL), but this amount of DMSO has produced aversive side effects (Hanslick et al., 
2009).  It may be necessary to administer twice daily injections of CX, however, the amount of 
DMSO that a mouse would receive over the course of the day would remain the same as a single 
injection of the same dose.  It is important to note that the majority of studies injecting treatments 
in neonatal or perinatal mouse models of DS use saline as a vehicle for the drug (Bianchi et al., 
2010; Stagni et al., 2016).  Thus, the use of DMSO as a CX-4945 vehicle in the current study 
makes it difficult to ascertain if the dose itself or the presence of DMSO led to null results.  
However, publications on Dyrk1a inhibitors administered to mouse models of DS, ALGERNON 
(unknown amount of DMSO), L41 (10% DMSO) and F-DANDY (unknown amount of DMSO), 
also used DMSO as a solvent (Nakano-Kobayashi et al., 2017; Naert et al., 2015).  Thus, alternate 
solvents to dissolve CX-4945 in should be explored, such as polyethylene glycol, or NaH2PO4 
buffer.  Future studies administering CX-4945 (or any Dyrk1a inhibitor dissolved in DMSO) could 
be strengthened by assessing any independent effects of DMSO on behavioral and cognitive effects 
by including a vehicle (i.e. saline) control.  
4.6 Limitations 
There are several limitations that future studies should be taken into consideration, such as 
potential stress effects of a treatment injection.  Stressful experiences during development and 
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throughout the lifespan can significantly alter the production of granule cells in the hippocampus 
(Gould et al., 1999).  For example, a single exposure of rat pups to a predator odor significantly 
decreased the production of granule cells in the DG 24 hours later (Tanapat et al., 1998).  Neonatal 
and adolescent stress in mice can alter the expression of genes involved in stress responses and 
impair performance on neurobehavioral tests (Juul et al., 2011; Yohn et al., 2017).  The current 
study did not include a non-injected control group, so it is unknown whether the stress of the 
injections themselves altered any of the observed phenotypes.  However, injections have been 
reported to cause a stress response in mice, so it will be important to establish any effects of 
injection stress in pre-weaning mice (Wokke, 2017; Meijer et al., 2006).  One approach could be 
to first analyze the phenotypes of non-injected euploid and trisomic mice.  If there are significant 
differences, this would establish the baseline phenotypes for each group, without any injection or 
treatment confounds. 
One of the biggest obstacles in the field is the lack of a Dyrk1a-specific kinase activity 
assay.  HPLC- and radioactive-based assays have been used in multiple studies to try and determine 
Dyrk1a kinase activity (Stringer et al., 2017; Stringer et al., 2015; Papadopoulos, 2011).  However, 
these methods report high variability within the assay, and the independent contribution of Dyrk1a 
activity cannot be accurately quantified.  Thus, these methods are more representative of general 
kinase activity within a given tissue.  While a more reliable Dyrk1a kinase activity assay is being 
developed, measuring the levels of known Dyrk1a substrates in order to obtain a semi-quantitative 
measure of Dyrk1a inhibition after treatment may be necessary.  For example, an elevation in 
Dyrk1a protein and a significant decrease in Cyclin D1 protein was observed in E11.5 Ts65Dn 
embryos, prompting a further investigation to elucidate the mechanism of Dyrk1a-mediate Cyclin 
D1 phosphorylation.  This relationship may not be present at all ages in Ts65Dn mice, therefore, 
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it will be important for future studies to assess the spatial and temporal specificity of specific 
Dyrk1a substrates in relation to Dyrk1a expression.   
If the focus is on targeting and inhibiting Dyrk1a, a more effective approach could be to 
target Dyrk1a at the onset of its overexpression and through its period of greatest overexpression 
for stronger conclusions to be drawn between the therapeutic administration and the measured 
phenotype.  Studies taking this approach would have to consider the translation of prenatal 
development between mice and humans.  Brain development in a P15 mouse is approximately 
equivalent to the a human newborn (Clancy et al., 2001).  Screening for DS in humans can occur 
as early as ~10-12 weeks of gestation by examining cell free DNA (cFDNA) (Norton et al., 2015).  
This gestational age translates to approximately E14-E15 in mice (Clancy et al., 2001; Clancy et 
al., 2007).  Although elevations in Dyrk1a protein levels have been detected at E11.5 in Ts65Dn 
embryos (Najas et al., 2015), E14-E15 may represent the earliest age at which therapeutics 
administered in mice could transition to a clinical setting. 
4.7 Conclusions 
The current study was the first to administer CX-4945 to Ts65Dn with the goal of 
improving phenotypes via Dyrk1a inhibition.  However, there are still several considerations 
regarding the efficacy of this therapeutic in Ts65Dn mice.  These CX-4945 considerations are 
similar to another therapeutic that is of interest in DS, EGCG.  A recent review by Stringer et al. 
(2017) highlights several factors that are contributing to the heterogeneity in studies administering 
EGCG to improve DS-related deficits.  Similar to this recent review on EGCG, factors such as the 
age of the mice, the amount of DMSO used to dissolve CX-4945, the length of treatment, the 
treatment group sizes and the route of administration are just a few factors that will need to be 
considered in future investigations testing CX-4945 in Ts65Dn mice. 
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This study demonstrated that level of Dyrk1a protein levels in Ts65Dn mice are both 
spatially and temporally dependent throughout perinatal and adolescent development.  These 
results showcase the importance of identifying specific time points to guide targeted therapeutics 
to inhibit Dyrk1a kinase activity.  This study also administered the novel Dyrk1a inhibitor, CX-
4945 at a time when Dyrk1a protein was elevated in Ts65Dn mice (P15-P18).  After 5 consecutive 
days of CX-4945 treatment, there were no significant improvements in locomotion, homing ability, 
or cell proliferation in the hippocampus.  However, these studies had moderate effect sizes and 
were found to be significantly underpowered.  This study has laid the groundwork for future studies 
to further explore the efficacy of CX-4945 treatment to Ts65Dn mice.  In addition, this study 
highlighted the importance of assessing the outcomes of trisomic mice produced from two different 
mating schemes (Ts65Dn x B6C3F1) and (Ts65Dn x B6C3.Dyrk1afl/fl).  This study will help 
advance the DS research field in its efforts to optimize Dyrk1a-targeted therapeutic administration 
and administer behavioral assessments that are appropriate for determining treatment efficacy.  
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APPENDIX 
For all graphs, panel “a” contains data that includes male mice from both (Ts65Dn x 
B6C3F1) and (Ts65Dn x B6C3.Dyrk1afl/fl) matings.  Panel “b” contains male offspring from 
(Ts65Dn x B6C3F1) matings.  The current study focused on reporting analysis from male euploid 
and trisomic Dyrk1afl/+ mice in the results section.  There was not sufficient statistical power to 
draw meaningful statistical conclusions about mice from a Ts65Dn background, however, this data 
is presented here to highlight potential differences in these mice versus male trisomic and euploid 
Dyrk1afl/+ mice. 
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Figure 15.  The trajectory of bodyweights across P15-P18 in offspring from (Ts65Dn x B6C3F1) 
matings and collapsed across mating schemes. 
 In Figure 15a, male Ts65Dn mice had significantly lower body weights and a slower 
growth rate over the five days of treatment compared to male euploid mice [main effect of 
genotype, F(1,50)=23.96, p<0.001; day x genotype interaction, F(4,200)=4.35, p=0.002].  
In addition, trisomic mice receiving CX-4945 had significantly lower body weights across 
all five treatment days [genotype x treatment interaction, (F(1,50)=4.87, p=0.0032)].  Both 
euploid groups weighed significantly more than both trisomic groups on P14, P15 and P18 
(p<0.05, as indicated by *).  Mice in the Eu+CX-4945 group continued to weigh 
significantly more than both trisomic groups at P16 and P17 (p<0.05, as indicated by ^), 
mice in the Eu+DMSO group were only significantly heavier than the Ts+CX-4945 groups 
on P16 and P17 (p<0.05, as indicated by &).  Figure 15b depicts the trajectory of male 
mice with a Ts65Dn background.  Data are represented as mean ± SEM. 
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Figure 16.  Dyrk1a protein levels of male P24 euploid and Ts65Dn mice from (Ts65Dn x B6C3F1) 
matings 
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Figure 17.  Dyrk1a protein levels of male P30 euploid and Ts65Dn from (Ts65Dn x B6C3F1) 
matings  
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Figure 18.  Dyrk1a protein levels of male P42 euploid and Ts65Dn offspring from (Ts65Dn x 
B6C3F1) matings 
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Figure 19.  Locomotor task-total distance travelled in offspring from (Ts65Dn x B6C3F1) matings 
and collapsed across both breeding schemes 
The average total distance travelled in the four treatment groups.  In Figure 19a, male 
euploid mice travelled significantly farther in the 10 minute task than the euploid groups, 
as indicated by the * [main effect of genotype, F(1,49)=4.77, p=0.034].  Figure 19b depicts 
the locomotor activity of male offspring from (Ts65Dn x B6C3F1) matings.  Data are 
represented as mean ± SEM. 
 
 
 
 
 
 
 
 
102 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 20.  The total time spent exploring both zones in offspring from (Ts65Dn x B6C3F1) 
matings and collapsed across backgrounds 
In Figure 20a, male euploid mice spent more time exploring both the home cage and new 
cage bedding zone versus trisomic mice, as indicated by the (*).   There were no significant 
differences between the groups on their preference to explore the home cage zone on trial 
1 or trial 2.  Figure 20b depicts male mice from a Ts65Dn background.  Data are 
represented as mean ± SEM. 
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Figure 21.  The number of midline crossings in offspring from (Ts65Dn x B6C3F1) matings and 
collapsed across both breeding schemes 
There were no significant differences between groups in the number of midline crossings 
in trial 1.  However, trisomic mice given DMSO had significantly more midline crossings 
in trial 2 than mice treated with CX-4945 [genotype x treatment interaction (1,50=70.91, 
p=0.029)], as indicated by the (*) in 21a.  Figure 21b depicts the number of total midline 
crossings in trial 2 in male offspring from (Ts65Dn x B6C3F1) matings.  Data are 
represented as mean ± SEM. 
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Figure 22.  Trial 1: total time spent exploring home zone in offspring from (Ts65Dn x B6C3F1) 
matings and collapsed across both breeding schemes 
In Figure 22a, on trial 1 euploid mice (collapsed across both breeding schemes) spent more 
time exploring the home zone versus trisomic mice, as indicated by the (*) [main effect of 
genotype, F(1,47)=5.4, p=0.024].  However, there were no significant main effects 
observed on the total time spent exploring the home zone in trial 2.  Figure 22b depicts the 
total time spent exploring the home zone in trial 1 in offspring from (Ts65Dn x B6C3F1) 
matings.  Data are represented as mean ± SEM. 
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Figure 23.  Trial 2: number of home visits in offspring from (Ts65Dn x B6C3F1) matings and 
collapsed across breeding schemes 
There were no significant effects on the number of home zone or new zone visits on trial 1 
in male mice collapsed across both breeding schemes.  Figure 23a depicts the number of 
home zone visits in trial 2, where both Eu+CX-4945 and Ts+DMSO treatment groups had 
significantly more visits to the home zone than the Ts+CX-4945 group [genotype x 
treatment interaction, F(1,47)=8.29, p=0.006].  Post hoc comparisons <0.05, as indicated 
by the (*).  Figure 23b depicts the number of home zone visits on trial 2 in male offspring 
from (Ts65Dn x B6C3F1).  Data are represented as mean ± SEM. 
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Figure 24.  T2: Total time spent exploring new zone in offspring from (Ts65Dn x B6C3F1) matings 
and collapsed across breeding schemes 
There were no significant differences on the total time spent exploring the new zone in trial 
1.  However, as seen in Figure 24a, male euploid mice collapsed across both breeding 
schemes spent significantly more time exploring the new zone in trial 2 than trisomic mice, 
as indicated by the (*) [main effect of genotype, (F(1,47)=9.89, p=0.003)].  Figure 24b 
depicts the total time spent exploring the new zone in trial 2 from male offspring from 
(Ts65Dn x B6C3F1) matings.  Data is represented as mean ± SEM. 
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Figure 25.  Trial 2: Total new zone visits in offspring from (Ts65Dn x B6C3F1) matings and 
collapsed across breeding schemes 
Figure 25a depicts the number of new zone visits in trial 2 (male mice collapsed across 
breeding schemes).  Euploid mice visited the new zone significantly more than trisomic 
mice, as indicated by the (*), [main effect of genotype, F(1,47)=7.38, p=0.009].  Figure 
25b depicts the number of new zone visits in trial 2 in male offspring from (Ts65Dn x 
B6C3F1) matings.  Data are represented as mean ± SEM. 
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Figure 26.  Time to first explore new zone in offspring from (Ts65Dn x B6C3F1) matings and 
collapsed across breeding schemes 
There were no significant effects between groups on the time to first enter the home zone 
or new zone on trial 1, nor were there any differences in the time taken to first enter the 
home zone on trial 2.  However, as seen in Figure 26a, male mice (collapsed across 
breeding schemes) treated with CX-4945 took significantly longer to enter the new zone 
on trial 2 versus mice treated with DMSO, as indicated by the (*), [main effect of treatment, 
F(1,47)=6.12, p=0.017)].  Figure 26b depicts the time to first explore the new zone in trial 
2 by male offspring from (Ts65Dn x B6C3F1) matings.  Data are represented as mean ± 
SEM. 
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Figure 27.  Total cell counts in offspring from (Ts65Dn x B6C3F1) matings and collapsed across 
breeding schemes 
In Figure 27a, collapsed across both breeding schemes, male euploid mice had significantly 
higher number of BrdU-labeled cells counted throughout the dentate gyrus versus trisomic 
controls (Figure 24a) [main effect of genotype, F(1,30)=4.2, p=0.049].  Euploid mice also 
had a significantly greater dentate gyrus volume than trisomics [main effect of genotype, 
F(1,30)=22.37, p<0.001].  Mice treated with CX-4945 also had significantly greater dentate 
gyrus volume than those treated with DMSO [main effect of treatment, F(1,30)=5.50, 
p=0.026)].  There were no significant main or interactive effects on the total number of 
slices counted.  Euploid mice treated with CX-4945 had significantly thicker slices 
[genotype x treatment interaction, F(1,33)=8.9, p=0.006].  LSD post hoc analysis showed 
that mice in the Eu+CX-4945 group had significantly thicker slices than the Eu+DMSO 
group (p=0.025).  There was a trend for mice treated with CX-4945 displaying lower cell 
density than mice treated with DMSO (p=0.07).  Figure 27b depicts the total cell counts in 
male offspring from (Ts65Dn x B6C3F1) matings.  Data are represented as mean ± SEM. 
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